Levi Strauss & Co. Appoints Elliott Rodgers to Board of Directors

Levi Strauss & Co. Appoints Elliott Rodgers to Board of Directors

SAN FRANCISCO–(BUSINESS WIRE)–
Levi Strauss & Co. (NYSE: LEVI) announced today that its board of directors has appointed Elliott Rodgers as a member of the board, effective immediately. Rodgers currently serves as chief information officer of Ulta Beauty, Inc. (NASDAQ: ULTA) and has more than a decade of experience in the retail industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201209006011/en/

Elliott Rodgers (Photo: Business Wire)

Elliott Rodgers (Photo: Business Wire)

“Elliott has deep knowledge of ecommerce, digital transformations and how to drive operational excellence in today’s omnichannel supply chain,” said Stephen C. Neal, chair of the board of Levi Strauss & Co. “His expertise in all of these areas will be invaluable as we focus on direct-to-consumer and continue to look for innovative ways to get our products to our consumers when, where and how they want them.”

Rodgers became chief information officer of Ulta Beauty in September after having held several supply chain roles since joining the company in November 2013, most recently serving as chief supply chain officer. Prior to joining Ulta Beauty, Rodgers was director of operations, Target.com & Mobile, at Target. In this role, he was responsible for Target’s ecommerce website and fulfillment operations and co-led Target’s omnichannel supply chain pilot programs. Previously, Rodgers held operational leadership roles spanning retail, financial services, and logistics at Target, Citibank and the United States Army.

“I am honored to join the board at Levi Strauss & Co., a company I’ve long admired as a leader of industry and culture,” Rodgers said. “I hope to complement the strength of the current board of directors and management team with my experience and passion as we all work toward the company’s continued success.”

Rodgers holds a B.S. in political science from the United States Military Academy at West Point and an MBA from the Harvard Business School.

About Levi Strauss & Co.

Levi Strauss & Co. is one of the world’s largest brand-name apparel companies and a global leader in jeanswear. The company designs and markets jeans, casual wear and related accessories for men, women and children under the Levi’s®, Dockers®, Signature by Levi Strauss & Co.™, and Denizen® brands. Its products are sold in more than 110 countries worldwide through a combination of chain retailers, department stores, online sites, and a global footprint of approximately 3,100 retail stores and shop-in-shops. Levi Strauss & Co.’s reported 2019 net revenues were $5.8 billion. For more information, go to http://levistrauss.com.

Media Contact:

Kelly Mason

Levi Strauss & Co.

(415) 501-7777

[email protected]

Investor Contact:

Aida Orphan

Levi Strauss & Co.

(800) 438-0349

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Fashion Retail Other Retail Department Stores Manufacturing Textiles

MEDIA:

Logo
Logo
Photo
Photo
Elliott Rodgers (Photo: Business Wire)

Five Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Virtual Annual Symposium

Five Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Virtual Annual Symposium

  • Detailed results of the Phase 2 FIGHT trial have been accepted for late breaker presentation during the Esophageal and Gastric cancer oral abstract session on January 15, 2021
  • Company to host webcast and conference call on January 15 at 1:30pm PST / 4:30pm EST

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced that detailed results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial evaluating bemarituzumab plus mFOLFOX6 chemotherapy in patients with fibroblast growth factor receptor 2b-positive (FGFR2b+), non HER2 positive (non HER2+) advanced gastric and gastroesophageal junction (GEJ) cancer will be featured during an oral podium presentation on January 15, 2021, at the ASCO Gastrointestinal Cancers Symposium being held virtually from January 15-17, 2021.

On November 10, 2020, Five Prime announced that the FIGHT trial met all three efficacy endpoints with bemarituzumab in combination with mFOLFOX6 chemotherapy providing statistically significant and clinically meaningful improvements in progression-free survival, overall survival, and objective response rate compared with mFOLFOX6 chemotherapy plus placebo in the front-line setting of patients with FGFR2b+, non HER2+ advanced gastric or GEJ cancer.

Bemarituzumab is the first and only investigational treatment targeting FGFR2b+ tumors. FGFR2b is overexpressed in approximately 30 percent of non HER2+ gastric and GEJ cancers. For these patients, no new front-line therapies have been approved in over a decade and systemic chemotherapy remains the standard of care. Five Prime and Roche Tissue Diagnostics (formerly Ventana Medical Systems) have also found that FGFR2b is overexpressed in numerous other cancers, including squamous non-small cell lung cancer, triple negative breast cancer, ovarian cancer, pancreatic cancer and intrahepatic cholangiocarcinoma. This represents additional potential areas for development of bemarituzumab beyond gastric and GEJ cancer.

The Company will host a conference call and live audio webcast on Friday, January 15, 2021 at 4:30pm (EST) / 1:30pm (PST) to review highlights from the presentation and will feature members of the Five Prime management team and Zev A. Wainberg, M.D., Associate Professor of Medicine at UCLA, Co-director of the Gastrointestinal Oncology Program and Director of Early Phase Clinical Research at the Jonsson Comprehensive Cancer Center, and a principal investigator of the trial.

Oral Presentation Details:

  • Title: Randomized Double-blind Placebo-Controlled Phase 2 Study of Bemarituzumab Combined with Modified FOLFOX6 (mFOLFOX6) in 1st Line (1L) Treatment of Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (FIGHT)
  • Abstract Number: 160
  • Oral Abstract Session: Esophageal and Gastric Cancer
  • Day and Time: Friday, January 15, 2021, 7:00am – 8:15am PST / 10:00am 11:15am EST
  • Author and Q&A Presenter:Zev A. Wainberg, M.D., Associate Professor of Medicine at UCLA, Co-director of the Gastrointestinal Oncology Program and Director of Early Phase Clinical Research at the Jonsson Comprehensive Cancer Center

Conference Call Information

Five Prime will host a conference call and live audio webcast on Friday, January 15, 2021 at 4:30pm EST / 1:30pm PST to discuss the detailed Phase 2 FIGHT trial results presented at ASCO GI. To participate in the conference call, please dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID: 2063209. To access the live webcast please visit https://investor.fiveprime.com/events-presentations.

An archived copy of the webcast will be available on Five Prime’s website beginning approximately two hours after the conference call. Five Prime will maintain an archived replay of the webcast on its website for at least 30 days after the conference call.

About the FIGHT Trial

The FGFR2b Inhibition in Gastric and Gastroesophageal Junction Cancer Treatment (FIGHT) trial (NCT03694522) was designed to evaluate the efficacy and safety of bemarituzumab in combination with modified FOLFOX6 (mFOLFOX6; leucovorin calcium, fluorouracil, and oxaliplatin) vs. mFOLFOX6 plus placebo in the front-line setting of patients with newly diagnosed FGFR2b positive, locally advanced or metastatic gastric and GEJ cancer.

Patients’ tumors were identified to be FGFR2b+ by immunohistochemistry and by FGFR2 gene amplification using a blood-based circulating tumor DNA assay. Testing was performed at a central laboratory.

The trial enrolled 155 patients in 15 countries across Asia, the European Union, and the United States.

About FGFR2b

The fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) pathway is implicated in the development and growth of cancer cells. FGFR2b is a form of FGFR found in epithelial cells, such as those in the stomach and skin. Data from the FIGHT trial suggests that approximately 30% of patients with non HER2+ gastroesophageal cancers overexpress FGFR2b.1 Five Prime and Roche Tissue Diagnostics have also found that FGFR2b is overexpressed in numerous other cancers, including squamous non-small cell lung cancer (NSCLC), triple negative breast (TNBC), ovarian, pancreatic and intrahepatic cholangiocarcinoma.

AboutBemarituzumab

Bemarituzumab (anti-FGFR2b, FPA144) is a first-in-class targeted antibody that blocks fibroblast growth factors (FGFs) from binding and activating FGFR2b, inhibiting several downstream pathways. Blocking FGFR2b activation is thought to slow cancer progression. Bemarituzumab is being developed in gastric and GEJ cancer as a targeted therapy for tumors that overexpress FGFR2b.

Five Prime granted an exclusive license to Zai Lab to develop and commercialize bemarituzumab in Greater China, and Zai Lab collaborated with Five Prime on the Phase 2 FIGHT trial in Greater China.

About Gastric Cancer and GEJ Cancer

Gastric cancer, also known as stomach cancer, is the third most common cause of cancer death worldwide and, excluding non-melanoma skin cancer, the fifth most common cancer worldwide, with over 1,000,000 new cases diagnosed each year.2 For HER2- patients, front-line therapy available today is the same systemic chemotherapy available since the 1990s.3,4

About Five Prime Therapeutics

Five Prime is a clinical stage biotechnology company relentlessly focused on rewriting the narrative for people with cancer. By tackling the tough scientific questions and untapped pathways, we aim to offer new hope by developing novel, breakthrough therapies that have potential to alter the course of disease in cancers with few treatment options. This vision is what defines us, and guides our research, clinical development and partnerships. To build a better tomorrow for people with cancer, we are teaming up with patients, physicians, scientists, and industry partners to make a meaningful difference in patients’ lives. Five Prime collaborates with leading global pharmaceutical companies and has therapies in pre-clinical and clinical development. For more information, please visit www.fiveprime.com.

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Forward-looking statements contained in this press release include statements regarding (i) the potential advancement of the development of bemarituzumab; (ii) the potential use of bemarituzumab, including in combination with other products, to treat patients; (iii) the potential development of bemarituzumab in indications in addition to gastric and GEJ cancer; (iv) the timing of the presentation of data for bemarituzumab; and (v) the extent of FGFR2b protein overexpression in certain patient populations. Actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during research, preclinical or clinical studies, changes in expected or existing competition, changes in the regulatory, pricing or reimbursement environment, and unexpected litigation or other disputes. In addition, while the company expects the COVID-19 pandemic to adversely affect its business operations and financial results, the extent of the impact on the company’s ability to advance its preclinical development and business and corporate development and other objectives will depend on future developments that are highly uncertain, and the company cannot predict with confidence the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries and the effectiveness of actions taken globally to contain and treat COVID-19. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

References

1. Data on file. Five Prime Therapeutics; 2020.

2. Bray F, Ferlay J, Soerjomataram I, et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492

3. Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):CD004064. doi:10.1002/14651858.CD004064.pub4

4. Drugs approved for stomach (gastric) cancer. Food and Drug Administration. Updated April 21, 2020. Accessed October 14, 2020. https://www.cancer.gov/about-cancer/treatment/drugs/stomach#1

Source: Five Prime Therapeutics, Inc.

Media and Investor Contact

Martin Forrest

VP, Investor Relations & Corporate Communications

Five Prime Therapeutics, Inc.

415-365-5625

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

Horizon Acquisition Corporation II Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing December 10, 2020

Horizon Acquisition Corporation II Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing December 10, 2020

NEW YORK–(BUSINESS WIRE)–
Horizon Acquisition Corporation II (NYSE: HZON.U) (the “Company”) announced that, commencing December 10, 2020, holders of the units sold in the Company’s initial public offering of 52,500,000 units, completed on October 22, 2020 and November 27, 2020, may elect to separately trade the Class A ordinary shares and warrants included in the units. Those units not separated will continue to trade on the New York Stock Exchange (“NYSE”) under the symbol “HZON.U,” and the Class A ordinary shares and warrants that are separated will trade on the NYSE under the symbols “HZON” and “HZON WS,” respectively. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into Class A ordinary shares and warrants.

The units were initially offered by the Company in an underwritten offering. Deutsche Bank Securities Inc. served as lead book-running manager for the offering. Credit Suisse Securities (USA) LLC and RBC Capital Markets, LLC served as book-running managers for the offering. A registration statement relating to the units and the underlying securities was declared effective by the Securities and Exchange Commission (the “SEC”) on October 19, 2020.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from: Deutsche Bank Securities Inc., Attn: Prospectus Department, 60 Wall Street, New York, New York 10005, Telephone: 1-800-503-4611, email: [email protected]; Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, Telephone: 1-800-221-1037, email: [email protected]; or RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, New York 10281, Telephone at 1-877-822-4089 or by email at [email protected].

About Horizon Acquisition Corporation II

Horizon Acquisition Corporation II is a newly incorporated blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company is sponsored by Horizon II Sponsor, LLC, an affiliate of Eldridge Industries, LLC (“Eldridge”). The Company will be led by Todd Boehly, the Co-founder, Chairman and Chief Executive Officer of Eldridge. While the Company may pursue an initial business combination target in any industry, it currently intends to concentrate its search for a target business operating in the media and entertainment industries, with a focus on differentiated product and services offerings.

Forward-Looking Statements

This press release may include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the SEC. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus relating to the Company’s initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Nadia Damouni

646-818-9217

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Alpine Materials Joins SiteOne Landscape Supply

Alpine Materials Joins SiteOne Landscape Supply

ROSWELL, Ga.–(BUSINESS WIRE)–
SiteOne® Landscape Supply, Inc. (NYSE: SITE) announced today that Alpine Materials has joined SiteOne. Alpine Materials serves the greater Dallas, Texas market from a single location focused on the distribution of mulches, soils and hardscape materials to landscape professionals.

“Alpine Materials is a terrific addition to SiteOne as they add market-leading hardscapes, landscape supplies and natural stone capability to our existing full line of products in the Dallas, Texas market,” said Doug Black, Chairman and CEO of SiteOne Landscape Supply.

“Alpine has a talented team that shares our passion for providing quality products, exceptional service and superior value to our customers,” said Black. “This is our ninth acquisition in 2020 and another step forward in our mission to become the best full product line distributor in the Green Industry.”

About SiteOne Landscape Supply:

SiteOne Landscape Supply (NYSE: SITE), is the largest and only national wholesale distributor of landscape supplies in the United States and has a growing presence in Canada. Its customers are primarily residential and commercial landscape professionals who specialize in the design, installation and maintenance of lawns, gardens, golf courses and other outdoor spaces. https://www.siteone.com/

Investor Relations:

SiteOne Landscape Supply, Inc.

470-270-7011

[email protected]

or

Media:

SiteOne Landscape Supply, Inc.

Greg Kirksey, 470-277-7164

Director, Communications

[email protected]

KEYWORDS: United States North America Georgia

INDUSTRY KEYWORDS: Other Construction & Property Residential Building & Real Estate Commercial Building & Real Estate Construction & Property

MEDIA:

G1 Therapeutics Presents Final Phase 2 Clinical Data on Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival at 2020 San Antonio Breast Cancer Symposium

Company also presents updated monotherapy data on investigational oral selective estrogen receptor degrader (SERD) rintodestrant for ER+, HER2- breast cancer

RESEARCH TRIANGLE PARK, N.C., Dec. 09, 2020 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported final data from its randomized Phase 2 trial of trilaciclib in metastatic triple-negative breast cancer (mTNBC) showing that trilaciclib significantly improved overall survival (OS) for patients treated with trilaciclib in combination with a chemotherapy regimen of gemcitabine/carboplatin (GC) compared with GC alone. These data were presented in a Spotlight Poster Discussion Session at the 2020 San Antonio Breast Cancer Symposium (SABCS). Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy.

“Triple-negative breast cancer is the most aggressive form of breast cancer, and there is a significant need for combination therapies that extend survival for women with either PD-L1 positive or PD-L1 negative tumors,” said Raj Malik, M.D, Chief Medical Officer and Senior Vice President, R&D. “Mature data from this Phase 2 trial showed trilaciclib improved overall survival in metastatic triple-negative breast cancer when given in combination with chemotherapy, regardless of PD-L1 status. We are excited to initiate a pivotal trial of trilaciclib in mTNBC in early 2021, with the goal of confirming the promising findings from this first trial.”

Trilaciclib in combination with chemotherapy improves o
verall survival
in
mTNBC

The randomized, open-label Phase 2 trial of trilaciclib in combination with a chemotherapy regimen of GC, a current standard of care for mTNBC, enrolled 102 patients who had received up to two prior chemotherapy regimens for locally recurrent or mTNBC. In this three-arm trial, all three groups received a chemotherapy regimen of GC. Patients were randomized to receive GC only (Group 1) or GC plus one of two dosing schedules of trilaciclib: trilaciclib administered on the day of chemotherapy (Group 2) or trilaciclib administered the day prior to and the day of chemotherapy (Group 3). Preliminary data were previously reported at the 2019 European Society for Medical Oncology congress and featured in a concurrent publication in The Lancet Oncology (press release here).

Key findings presented in the 2020 SABCS poster included:

  • Compared to GC alone (Group 1), OS was improved in both trilaciclib arms (Groups 2 and 3) (Group 2: HR=0.31, p=0.0016; Group 3: HR=0.40, p=0.0004). Median OS was 12.6 months in Group 1, not reached for Group 2, and 17.8 months in Group 3. The median OS for Groups 2 and 3 combined was 19.8 months (HR=0.37, p<0.0001). OS findings in patients receiving trilaciclib were consistent with previously-reported data from this trial. The median OS for GC alone (Group 1, 12.6 months) was consistent with the previous trial findings and historical data.
  • In a subset analysis based on PD-L1 status, patients with both PD-L1-positive and PD-L1-negative tumors treated with trilaciclib and GC demonstrated improvement in OS compared to patients receiving GC alone, with the PD-L1-positive subset achieving statistically significant improvement.
  • In a subset analysis based on CDK4/6 status, OS was similar in tumors categorized as CDK4/6 dependent, independent, or indeterminate. In this analysis, trilaciclib did not impair the efficacy of GC, regardless of CDK4/6 status.
  • Data from T-cell clonality analysis suggest that administering trilaciclib prior to chemotherapy enhanced immune system function.

Registrational trial in
mTNBC
to begin in
20
21

This randomized, double-blind trial will evaluate trilaciclib in combination with a chemotherapy regimen of GC in two separate patient cohorts: 1) first-line treatment in patients with mTNBC who have not received a PD-1/PD-L1 inhibitor; and 2) second-line treatment in patients with mTNBC who have received a PD-1/PD-L1 inhibitor. All patients will receive treatment until disease progression. The company expects to enroll a total of approximately 250 participants in the trial, with the majority (approximately 170) in the first-line cohort. The trial will enroll patients who are both PD-L1-positive and PD-L1-negative.

The primary endpoint of this trial is overall survival; secondary endpoints include patient-reported outcomes measures, safety/tolerability, myelopreservation measures, and progression-free survival. The pre-specified statistical plan for the trial will allow for separate analysis of the two cohorts.

Updated result
s from rintodestrant monotherapy for ER+, HER2- breast cancer

The company also presented updated monotherapy data from the Phase 1 portion of its ongoing clinical trial of rintodestrant, a potential best-in-class oral selective estrogen receptor degrader (SERD) in development for the treatment of ER+, HER2- breast cancer. The findings included data from the 600 mg and 1,000 mg dose expansion cohorts of the trial that supported the company’s decision to advance the 800 mg dose in further development, including the ongoing rintodestrant/palbociclib arm of this trial.

Key clinical findings from the 67-patient trial (poster) included:

  • Safety and tolerability findings across all doses, including the 600 mg and 1,000 mg expansion cohorts, were consistent with previously reported data.
  • In a heavily pre-treated patient population, rintodestrant showed evidence of clinical activity, including 5% (3/67) of patients with confirmed partial responses, 36% (24/67) with stable disease, and a clinical benefit rate of 30% (20/67).

About G1 Therapeutics

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies. Trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy. Trilaciclib received Breakthrough Therapy Designation and is under review by the U.S. Food and Drug Administration (FDA) with a PDUFA action date of February 15, 2021. Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. In 2020, the company out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.

G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, those relating to the therapeutic potential of trilaciclib, rintodestrant and lerociclib, the timing of marketing applications in the U.S. and Europe for trilaciclib in SCLC, trilaciclib’s possibility to improve patient outcomes across multiple indications, including in metastatic triple-negative breast cancer, rintodestrant’s potential to be best-in-class oral SERD for treatment of ER+, HER2- breast cancer, our reliance on partners to develop and commercial licensed products, and the impact of pandemics such as COVID-19 (coronavirus), are based on the company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause the company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the company’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein and include, but are not limited to, the company’s ability to complete clinical trials for, obtain approvals for and commercialize any of its product candidates; the company’s initial success in ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials; the inherent uncertainties associated with developing new products or technologies and operating as a development-stage company; and market conditions. Except as required by law, the company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contact:

Jeff Macdonald
G1 Therapeutics, Inc.
Senior Director, Investor Relations & Corporate Communications
919-907-1944
[email protected]



Alamos Gold Provides 2021 Production and Operating Guidance

All amounts are in United States dollars, unless otherwise stated.

TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) — Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) today provided 2021 production and operating guidance.

“This has been a transformational year for Alamos. Operationally, we continue to execute and remain on track to achieve our 2020 production, cost, and capital guidance. We also delivered on several significant catalysts which have solidified our strong outlook. We completed the lower mine expansion at Young-Davidson, transitioned to strong free cash flow generation in the third quarter, and began construction on the high-return La Yaqui Grande project and Phase III Expansion at Island Gold,” said John A. McCluskey, President and Chief Executive Officer.

“The ramp up of mining rates at Young-Davidson is expected to drive a 17% increase in our production in 2021. Young-Davidson will also be a key driver of strong ongoing free cash flow generation supporting both higher returns to shareholders and the reinvestment into high-return growth opportunities at Island Gold and Mulatos. These investments form a key part of our balanced approach to capital allocation which will provide further growth and returns that are sustainable over the long term,” Mr. McCluskey added.

20
20
Operational Update

  • P
    roduction and cost
    s remain on track to achieve full year 2020
    guidance

20
2
1
Guidance Overview

  • Strong production growth with
    guidance of
    4
    70
    ,000
    to
    510
    ,000
    ounce
    s
    of gold
    : a 17% increase from 2020 guidance (based on the mid-point), driven by significantly higher production at Young-Davidson with the completion of the lower mine expansion in July 2020
  • Lower costs with t
    otal cash cost guidance of $
    7
    10
    to $
    76
    0
    per ounce
    : an 8% decrease from 2020 guidance (based on the mid-point) reflecting lower costs at Young-Davidson as mining rates continue to ramp up from the new lower mine infrastructure. This includes approximately $25 per ounce of COVID-19 testing and other related health and safety costs across all operations
  • A
    ll-in sustaining cost
    (“AISC”)
    guidance of $1,0
    25
    to $1,0
    75
    per ounce
    : consistent with 2020 guidance with lower total cash costs offset by higher sustaining capital at Mulatos, which includes $50 per ounce globally related to El Salto pre-stripping activities
  • Total capital
    guidance
    ,
    excluding
    capitalized exploration,
    of $
    320
    to $
    350
    million
    : an increase from 2020 guidance of $185 to $215 million primarily reflecting higher capital spending on internal growth initiatives including La Yaqui Grande and the Phase III Expansion at Island Gold. This total capital budget includes:

    • Sustaining capital guidance of $110 to $125 million: a temporary increase from guidance of $80 to $95 million in 2020 to complete $25 million of stripping activities at the El Salto portion of the Mulatos pit
    • Growth capital guidance of $210to $225million: an increase from the 2020 guidance of $105 to $120 million in 2020 reflecting the ramp up of construction of La Yaqui Grande and the Phase III Expansion at Island Gold. This is partly offset by lower growth capital at Young-Davidson with the completion of the lower mine expansion in 2020
  • Exploration budget increased to
    $
    50
    million
    : up from the initial 2020 exploration budget of $36 million, reflecting increased spending at Island Gold, Mulatos, and Lynn Lake, as well as Young-Davidson, with improved access for underground drilling from the lower mine
  • Strong ongoing free cash flow
    : La Yaqui Grande and the Phase III Expansion at Island Gold are expected to be self-funded by their respective operations at current gold prices with Young-Davidson providing strong ongoing free cash flow generation
  • Increased dividend of US$0.02 per share (US
    $0.08
    annually) to be paid out later this month, representing a 33% increase from the previous quarter: with the higher dividend rate supported by the Company’s strong free cash flow outlook at current gold prices

Outlook
to 2025

  • Production growth to
    approximately
    6
    00,000 ounces per year from existing operating mines
    in 2025
    : driven by low cost growth at Island Gold with the completion of the Phase III Expansion
  • Additional growth potential to approximately 750,000 ounces per year in 2025: incorporating growth from the Lynn Lake project with permitting expected to be completed in 2022
  • Declining cost profile: the completion of La Yaqui Grande and the Phase III Expansion are expected to drive all-in sustaining costs lower to approximately $800 per ounce by 2025
  • Fully funded organic growth
    : the Company’s growth initiatives are expected to be funded internally given its strong balance sheet and free cash flow outlook

20
2
1
Guidance

    2021 Guidance


2020 Revised Guidance (4)
  Young-Davidson Island Gold Mulatos Other

(2)
Total Total
Gold production
(000’s ounces)
190-205 130-145 150-160   470-510 405-435
Cost of sales, including 
amortization   (in millions)(3)
$255 $108 $177 $
540
$
487
Cost of sales, including 
amortization
($ per ounce)
(3)
$1,290 $785 $1,145 $
1,105
$
1,160
Total cash costs
($ per ounce)
(1)
$790-840 $430-480 $840-890 $710-760 $780-820
All-in sustaining costs

($ per ounce)
(1)
      $1,025-1,075 $1,030-1,070
Mine-site all-in sustaining costs

($ per ounce)
(1),(2)
$1,000-1,050 $750-800 $1,060-1,110    
Amortization costs

($ per ounce)
(1)
$475 $330 $280 $
370
$
365
Corporate & Administrative
(in millions)
        $
20
$
20
Capital expenditures
(in millions)
           
Sustaining capital(1) $40-45 $40-45 $30-35 $110-125 $80-95
Growth capital(1) $25-30 $80-85 $95-100 $10 $210-225 $105
-1
20
Total sustaining & growth capital

(1)
$65-75 $120-130 $125-135 $10 $320-350 $185-215
Capitalized exploration(1) $7 $20  – $7 $
34
$
20
Total capital expenditures

(1)
$72-82 $140-150 $125-135 $17 $354-384 $205
-2
35

(1)  Refer to the “Non-GAAP Measures and Additional GAAP” disclosure at the end of this press release for a description of these measures.
(2)  For the purposes of calculating mine-site all-in sustaining costs at individual mine sites, the Company does not include an allocation of corporate and administrative and share based compensation expenses to the mine sites.
(3)  Cost of sales includes mining and processing costs, royalties, and amortization expense, and is calculated based on the mid-point of total cash cost guidance.
(4) 2020 guidance was revised on July 29, 2020 reflecting COVID-19 related temporary operational suspensions & delays during Q2 2020.

The 2021 production forecast and operating cost estimates are based on the following assumptions:

Foreign Exchange Rate 2021 Operating Sites Foreign Currency Exposure Change Free Cash Flow Sensitivity
USD/CAD $0.75:1 95% $0.05 ~$30 million
MXN/USD 21.0:1 40% 1.00 ~$3 million

Current foreign exchange and gold hedging commitments

The Company has entered into the following foreign exchange and short term hedging arrangements to date:

  • Canadian dollar
    : approximately 8% of Canadian dollar-denominated operating and capital costs for 2021 have been hedged, ensuring a maximum USD/CAD foreign exchange rate of $0.76:1 and allowing the Company to participate in weakness in the USD/CAD up to a rate of $0.73:1.
  • Mexican peso: approximately 45% of Mexican peso-denominated operating and capital costs in 2021 have been hedged, ensuring a minimum MXN/USD foreign exchange rate of 21.0:1 and allowing the Company to participate in weakness in the MXN/USD up to a rate of 25.4:1.
  • Gold collar contracts: The Company also periodically enters into short term gold hedging arrangements. Currently, the Company has hedged 31,500 ounces during the first half of 2021, ensuring an average minimum gold price of $1,730 per ounce and participation up to an average gold price of $2,070 per ounce.

Gold production and costs are expected to be relatively consistent on a company-wide basis throughout 2021. Total cash costs and all-in sustaining costs include approximately $25 per ounce of COVID-19 testing and other related health and safety costs across all three operating mines.

Capital spending is expected to be slightly higher during the first half of the year, reflecting pre-stripping activities at Mulatos, and trend lower in the second half of the year. Accordingly, all-in sustaining costs are expected to be slightly lower in the second half of 2021.


Young-Davidson

Young-Davidson   Q3 YTD 2020 2020
Revised
G
uidance (4)
2021
G
uidance
Gold Production 000 oz 88 135 – 145 190 – 205
         
Cost of Sales

(1)
$/oz $1,617 $
1,490
$
1,
290
Total Cash Costs

(2)
$/oz $1,145 $990-1,030 $790-840
Mine-site AISC

(2)


,(3)
$/oz $1,370 $1,180-1,220 $1,000-1,050
         
Tonnes of ore processed tpd 5,298 4,000-7,500 7,500-8,000
Grade processed g/t Au 2.01 2.35-2.65 2.20-2.65
Average recovery rate % 92% 90-92% 90-92%
         
Sustaining
capital

(


2)
$ millions $19 $30-35 $
40

45
Growth capital

(2)
$ millions $63 $45-50 $
25
-3
0
Total
sustaining & growth
capital

(2)

(ex
.
exploration)
$ millions $82 $75-85 $65-75
         
Capitalized
exploration

(


2)
$ millions $
1
$
7

(1)  Cost of sales includes mining and processing costs, royalties, and amortization expense, and is calculated based on the mid-point of total cash cost guidance.
(2)  Refer to the “Non-GAAP Measures and Additional GAAP” disclosure at the end of this press release and the Q3 2020 MD&A for a description and calculation of these measures.
(3)  For the purposes of calculating mine-site all-in sustaining costs at individual mine sites, the Company does not include an allocation of corporate and administrative and share based compensation expenses to the mine sites.
(4) 2020 guidance was revised on July 29, 2020 reflecting COVID-19 related temporary operational suspensions & delays during Q2 2020.

Gold production at Young-Davidson is expected to increase by 41% in 2021 (based on the mid-point of guidance) driven by significantly higher mining rates following the completion of the lower mine expansion in July 2020. Underground mining rates are expected to ramp up from 7,500 tpd early in 2021 to design rates of 8,000 tpd in the second half of the year. Grades mined and processed are expected to increase through the year, ranging between 2.20 and 2.65 grams per tonne of gold (“g/t Au”). Increasing mining rates and grades are expected to drive gold production higher through the year.

Total cash costs and mine-site all-in sustaining costs are expected to decrease 19% and 15% respectively from 2020 (based on the mid-point of guidance), reflecting higher mining rates and productivity improvements with the transition to the lower mine infrastructure. Costs are expected to decrease through the year reflecting the above noted increasing mining rates and grades.

Capital spending in 2021 (excluding exploration) is expected to be between $65 and $75 million, down significantly from 2020. The 2021 budget includes $14 million of spending on the new tailings facility (“TIA 1”) which will be utilized for the remaining mine life at Young-Davidson. Construction of TIA 1 is expected to be completed by the end of 2021.

Capital spending is expected to decrease in the second half of 2021 with approximately 55% of the capital budget planned for the first half of the year. With the completion of the lower mine expansion in 2020 and TIA 1 in 2021, capital spending is expected to continue to trend lower over the next few years to a long-term rate of $40 to 50 million per year.

Between higher production, lower costs and lower capital, Young-Davidson is expected to generate record mine-site free cash flow of approximately $120 million in 2021 at an $1,800 per ounce gold price.


Island Gold

Island Gold   Q3 YTD 2020 2020
Revised
G
uidance (4)
2021
G
uidance
Gold Production 000 oz 98 130-14
0
130-145
         
Cost of Sales

(1)
$/oz $806 $
840
$
785
Total Cash Costs

(2)
$/oz $438 $480-520 $430-480
Mine-site AISC

(2)


,(3)
$/oz $653 $740-780 $750-800
         
Tonnes of ore processed tpd 1,026 1,150-1,200 1,200
Grade processed g/t Au 11.52 10.0-11.0 9.0-11.0
Average recovery rate % 97% 96-97% 96-97%
         
Sustaining
capital

(


2)
$ millions $21 $35-40 $40-45
Growth capital

(2)
$ millions $25 $
35-40
$80-85
Total
sustaining & growth
capital

(2)

(ex. exploration)
$ millions $46 $
70-80
$120-130
         
Capitalized exploration

(2)
$ millions $8 $
15
$
20

(1)  Cost of sales includes mining and processing costs, royalties, and amortization expense, and is calculated based on the mid-point of total cash cost guidance.
(2)  Refer to the “Non-GAAP Measures and Additional GAAP” disclosure at the end of this press release and the Q3 2020 MD&A for a description and calculation of these measures.
(3)  For the purposes of calculating mine-site all-in sustaining costs at individual mine sites, the Company does not include an allocation of corporate and administrative and share based compensation expenses to the mine sites.
(4) 2020 guidance was revised on July 29, 2020 reflecting COVID-19 related temporary operational suspensions & delays during Q2 2020.

Gold production is expected to be in the same range as 2020 guidance and consistent with the parameters outlined in the Phase III Expansion study released in July. Mining rates are expected to be consistent with the 2020 budget and remain stable through the year. Grades mined are expected to be above the Mineral Reserve grade in the first quarter and trend lower through the year to average slightly above 10 g/t Au for the full year. As a result, approximately 60% of full year production is expected to be in the first half of 2021.

Total cash costs and mine-site all-in sustaining costs are also expected to be similar to 2020 guidance and consistent with the Phase III Expansion study.

Capital spending at Island Gold (excluding exploration) is expected to be between $120 and $130 million in 2021, consistent with the Phase III Expansion study. As planned, this represents an increase from the 2020 budget, reflecting the ramp up of spending on the Phase III Expansion. This includes advancing detailed engineering on the shaft infrastructure and paste plant, procurement of long lead time items, and starting construction on the hoist house and shaft sinking setup. A number of additional surface and underground infrastructure projects are also expected to be completed in 2021 to support the expanding operation. These include the expansion of the tailings facility, the underground workshop, and additional camp improvements.


Mulatos District

Mulatos District   Q3 YTD 2020 2020
Revised
G
uidance (5)
2021
G
uidance
Gold Production oz 120 140-150 150-160
         
Cost of Sales

(1)
$/oz $1,075 $
1,135
$
1,
145
Total Cash Costs

(2)
$/oz $772 $840-880 $840-890
Mine-site AISC

(2)


,(3)
$/oz $928 $940-980 $1,060-1,110
         
Tonnes of ore stacked tpd 19,484 22,000 21,000
Grades stacked g/t Au 1.17 0.9-1.1 0.8-1.
2
Combined Recovery Ratio % 59% 60
%
6
0
%
         
Sustaining capital

(2)
$ millions $15 $15-20 $30-35
Growth capital

(2),(


4


)
$ millions $6 $
1
5
-20
$95-100
Total
sustaining & growth
capital

(2),(4)

(ex. exploration)
$ millions $21 $
30-40
$125-135
         
Capitalized exploration

(2)
$ millions $1

(1)  Cost of sales includes mining and processing costs, royalties, and amortization expense, and is calculated based on the mid-point of total cash cost guidance.
(2)  Refer to the “Non-GAAP Measures and Additional GAAP” disclosure at the end of this press release and the Q3 2020 MD&A for a description and calculation of these measures.
(3)  For the purposes of calculating mine-site all-in sustaining costs at individual mine sites, the Company does not include an allocation of corporate and administrative and share based compensation expenses to the mine sites.
(4)  Growth capital guidance of $95-100 million in 2021 is all related to construction of La Yaqui Grande.
(5) 2020 guidance was revised on July 29, 2020 reflecting COVID-19 related temporary operational suspensions & delays during Q2 2020.

The Mulatos District is expected to produce 150,000 to 160,000 ounces of gold in 2021, consistent with long term guidance and up 7% from 2020 guidance (based on the mid-point). Cerro Pelon, the Mulatos pit, and surface stockpiles will be the main contributors to production in 2021. Grades stacked are expected to range between 0.8 g/t Au and 1.2 g/t Au and trend lower through the year resulting in higher production during the first half of the year.

Total cash costs are expected to be consistent with 2020 guidance and stable throughout 2021. Mine-site all-in sustaining costs are expected to increase from 2020 and be significantly higher during the first half of 2021, reflecting $25 million of spending to complete pre-stripping of the El Salto area of the Mulatos pit. This represents the majority of the 2021 sustaining capital budget. El Salto is expected to start contributing ore during the second half of the year.

Capital spending across the Mulatos District is expected to be between $125 and $135 million in 2021. This is an increase from 2020 reflecting higher sustaining capital to complete the above noted pre-stripping activities at El Salto and $95 to $100 million of growth capital for construction of La Yaqui Grande. Development of La Yaqui Grande started in the third quarter of 2020 with pre-stripping of the open pit area commencing in the fourth quarter. The focus in 2021 will be ongoing stripping activities, and construction of the camp facilities, heap leach facility and crushing circuit. La Yaqui Grande remains on track to begin ramping up low-cost production in the third quarter of 2022.

202
1
Global
Operating and Development
Capital
Budget

    2021 Guidance


20
20
Revised

Guidance (2)
  Sustaining Capital

(1)
Growth C
a
pital

(1)



Total
Total
Operating Mines
(in millions)
       
Young-Davidson $40-45 $25-30 $65-75 $75-85
Island Gold $40-45 $80-85 $120-130 $70-80
Mulatos $30-35 $95-100 $125-135 $30-40
Total – Operating Mines $
1
10

1
2
5
$
20
0

2
15
$310-340 $175-205
Development Projects
(in millions)
         
Lynn Lake $6 $
6
$3
Other $4 $
4
$7
Total – Development Projects $
10
$
10
$10
Capitalized Exploration

(1)

(in millions)
         
Young-Davidson $7 $
7
$1
Island Gold $20 $
2
0
$15
Mulatos  –  
Lynn Lake $7 $
7
$4
Total – Capitalized Exploration

(1)
$
3
4
$
3
4
$20
Total Consolidated Budget $
1
10

1
2
5
$
24
4

2
59
$
354

384
$205-235

(1)  Refer to the “Non-GAAP Measures and Additional GAAP” disclosure at the end of this press release and the Q3 2020 MD&A for a description and calculation of these measures.
(2) 2020 guidance was revised on July 29, 2020 reflecting COVID-19 related temporary operational suspensions & delays during Q2 2020.

20
2
1
Capital Budget for Development Projects

Capital spending on the Company’s development projects, excluding exploration, is expected to total $10 million. This includes $6 million focused on advancing the Lynn Lake project through the permitting process with the majority of the remainder focused on permitting and community engagement at Esperanza. Additionally, the Company expects to spend $34 million in capitalized exploration, of which the majority is earmarked for Island Gold, followed by Young-Davidson and Lynn Lake.  

Lynn Lake Development Budget

The 2021 capital budget for Lynn Lake is $13 million, including $6 million for development activities and $7 million for exploration. Development spending will be focused on ongoing environmental baseline work to support permitting of the project, community engagement, and other engineering and geotechnical work. The Environmental Impact Study (“EIS”) for the project was submitted in the second quarter of 2020, initiating a permitting process which is expected to take approximately two years. This would be followed by approximately two years of construction assuming a positive construction decision.

Kirazlı
Development Budget

On October 14, 2019, the Company suspended all construction activities on its Kirazlı project pending the renewal of its Turkish mining concessions which expired on October 13, 2019. Although the mining concessions have not been revoked and can be renewed following this expiration date, no further construction activities can be completed until the concessions have been renewed.

The Company has met all the regulatory requirements and conditions for the concessions to be renewed and reasonably expected the renewal by the expiration date. The communities local to the Kirazlı project remain supportive. As such, the Company is working with the Turkish Department of Energy and Natural Resources on securing the renewal of the mining concessions which will allow for a resumption of construction activities.

The Company will provide updated guidance on the construction schedule and budget for Kirazlı following the receipt of the concession renewal and resumption of construction activities. Holding costs for the Company’s Turkish projects are expected to total approximately $0.7 million per month.

20
2
1
Exploration Budget

The 2021 global exploration budget has increased to $50 million from the initial 2020 budget of $36 million. The increase reflects larger exploration programs at each of Island Gold, Mulatos, Young-Davidson and Lynn Lake. Island Gold remains the primary focus and continues to account for the largest portion of the budget with $25 million planned for 2021. This is followed by a $9 million budget at Mulatos and $7 million budgeted at each of Young-Davidson and Lynn Lake. Approximately 70% of the 2021 budget will be capitalized.

Island Gold

A total of $25 million has been budgeted in 2021 for surface and underground exploration at Island Gold, up from the initial 2020 budget of $21 million. The focus remains on continuing to define new near mine Mineral Resources across the two-kilometre long Island Gold Main Zone, as well as advancing and evaluating several regional targets. The 2021 exploration budget includes 27,500 metres (“m”) of surface directional drilling, 24,000 m of underground directional drilling, 28,000 m of underground exploration drilling, and 900 m of underground exploration development to extend drill platforms on the 620, 790, and 840-levels.

Surface and underground exploration drilling completed in 2020 was successful in further extending high grade gold mineralization laterally and down-plunge of the Island Gold Deposit. This included the best surface exploration hole to date, MH25-04 grading 28.97 g/t Au (26.89 g/t cut) over 21.76 m true width, and MH25-03 grading 15.38 g/t Au (14.19 g/t cut) over 15.02m (both previously reported). These intercepts have extended high-grade gold mineralization over significantly greater widths in Island East up to 100 m down-plunge from the nearest Inferred Mineral Resource block (719,800 ounces grading 18.74 g/t Au (1.2 million tonnes) as of December 31, 2019).

The 2021 surface and underground exploration drilling program will continue to test the lateral and down-plunge extensions of Island Main, West, and East.

A significantly larger regional exploration program including 25,000 m of drilling is also planned in 2021. The focus will be on evaluating and advancing exploration targets outside the main Island Gold Mine area on the 9,511-hectare Island Gold property.

Mulatos

A total of $9 million has been budgeted at Mulatos for exploration in 2021. This includes 19,400 m of drilling focused on the Mulatos near-mine area, and regional targets including Carricito and Halcon.

Several regional exploration targets have been identified from a property-wide VTEM geophysical survey that was completed in late 2018. A focus of the 2021 regional exploration program will be to further evaluate these targets through systematic mapping, sampling, and ground geophysics with the objective of defining drill targets.

Young-Davidson

A total $7 million has been budgeted for exploration at Young-Davidson in 2021. This represents the first significant exploration program at Young-Davidson since 2011 with the focus over the last several years on completing the lower mine expansion and with improved access to drill from underground at depth.

The 2021 program includes 13,000 m of underground exploration drilling, 10,000 m of underground directional drilling, 3,000 m of surface drilling, and 560 m of underground exploration development to extend drill platforms on the 9220-level. The focus of the underground exploration drilling program will be to expand Mineral Reserves and Mineral Resources in five target areas that have been identified within proximity to existing underground infrastructure. The objective of the underground directional drilling program will be to utilize drill platforms that have been established within the lower mine infrastructure to target mineralization down-plunge of the Mineral Reserves and Resources, beyond the extent of any previous exploration drilling.

In addition, 3,000 m of surface drilling is planned to test near-surface targets to both the east and west along strike from Young-Davidson.

Lynn Lake

A total of $7 million, including 17,000 m of drilling, has been budgeted for exploration at the Lynn Lake project in 2021. Testing exploration targets in proximity to the Gordon and MacLellan deposits will remain the primary focus with the goal of adding to Mineral Resources. The exploration program will also further evaluate the Burnt Timber and Linkwood deposits, including updating the geological models, and defining and testing exploration targets with the objective of expanding Mineral Resources at both deposits. The Burnt Timber and Linkwood deposits contained an Inferred Mineral Resource of 1.6 million ounces grading 1.1 g/t Au (44 million tonnes) as of December 31, 2019 and represent potential upside to the 2017 Feasibility Study.

The other key area of focus for 2021 is the continued evaluation and advancement of a pipeline of prospective exploration targets within the 58,500-hectare Lynn Lake Property, building on the exploration work completed in 2020.

Qualified Persons

Chris Bostwick, Alamos’ Vice President, Technical Services, who is a qualified person within the meaning of National Instrument 43-101 Standards of Disclosure for Mineral Projects, has reviewed and approved the scientific and technical information contained in this press release.

About Alamos

Alamos is a Canadian-based intermediate gold producer with diversified production from three operating mines in North America. This includes the Young-Davidson and Island Gold mines in northern Ontario, Canada and the Mulatos mine in Sonora State, Mexico. Additionally, the Company has a significant portfolio of development stage projects in Canada, Mexico, Turkey, and the United States. Alamos employs more than 1,700 people and is committed to the highest standards of sustainable development. The Company’s shares are traded on the TSX and NYSE under the symbol “AGI”.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Scott K. Parsons  
Vice President, Investor Relations  
(416) 368-9932 x 5439  

The TSX and NYSE have not reviewed and do not accept responsibility for the adequacy or accuracy of this release.

Cautionary Note

This news release contains or incorporates by reference “forward-looking statements” and “forward-looking information” as defined under applicable Canadian and U.S. securities laws which are referred to herein as “forward looking-looking statements”. All statements, other than statements of historical fact, which address events, results, outcomes or developments that the Company expects to occur are, or may be deemed to be, forward-looking statements and are generally, but not always, identified by the use of forward-looking terminology such as “expect”, “is expected”, “outlook”, “on track”, “continue”, “ongoing”, “will”, “believe”, “anticipate”, “intend”, “estimate”, “forecast”, “budget”, “target”, “plan” or variations of such words and phrases and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved or the negative connotation of such terms.

Forward-looking statements include information as to strategy, plans or future financial or operating performance, such as the Company’s production forecasts and plans, expected sustaining costs, expected improvements in cash flows and margins, expectations of changes in capital expenditures, expansion plans, project timelines, and expected sustainable productivity increases, expected increases in mining activities and corresponding cost efficiencies, expected drilling targets, forecasted cash shortfalls and the Company’s ability to fund them, cost estimates, projected exploration results, projected development and permitting timelines, expected production rates and use of the stockpile inventory, expected recoveries, sufficiency of working capital for future commitments, Mineral Reserve and Mineral Resource estimates, and other statements that express management’s expectations or estimates of future performance.

Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by management at the time of making such statements, are inherently subject to significant business, economic, technical, legal, political and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements, and undue reliance should not be placed on such statements and information.

Such factors and assumptions underlying the forward-looking statements in this news release, but are not limited to: changes to current estimates of Mineral Reserves and Resources; changes to production estimates (which assume accuracy of projected ore grade, mining rates, recovery timing and recovery rate estimates and may be impacted by unscheduled maintenance, labour and contractor availability and other operating or technical difficulties); operations may be exposed to new diseases, epidemics and pandemics, including the effects and potential effects of the global COVID-19 widespread pandemic; the impact of the COVID-19 pandemic on the broader market and the trading price of the Company’s shares; provincial, state and federal orders or mandates (including with respect to mining operations generally or auxiliary businesses or services required for the Company’s operations) in Canada, Mexico, the United States and Turkey; the duration of regulatory responses to the COVID-19 pandemic; government and the Company’s attempts to reduce the spread of COVID-19 which may affect many aspects of the Company’s operations including the ability to transport personnel to and from site, contractor and supply availability and the ability to sell or deliver gold dore bars; fluctuations in the price of gold or certain other commodities such as, diesel fuel, natural gas and electricity; changes in foreign exchange rates (particularly the Canadian dollar, U.S. dollar, Mexican peso and Turkish Lira); the impact of inflation; changes in the Company’s credit rating; any decision to declare a dividend; employee and community relations (including maintaining social license to operate in Turkey); labour and contractor availability (and being able to secure the same on favourable terms); litigation and administrative proceedings; disruptions affecting operations; availability of and increased costs associated with mining inputs and labour; development delays at the Kirazlı project or those that may be related to future developments and expansion at Island Gold mine; inherent risks and hazards associated with mining and mineral processing including environmental hazards, industrial accidents, unusual or unexpected formations, pressures and cave-ins; the risk that the Company’s mines may not perform as planned; uncertainty with the Company’s ability to secure additional capital to execute its business plans; the speculative nature of mineral exploration and development, risks in obtaining and maintaining necessary licenses, permits and authorizations, contests over title to properties; the renewal of the Company’s mining concessions in Turkey; timely resumption of construction and development at the Kirazlı project; expropriation or nationalization of property; political or economic developments in Canada, Mexico, the United States, Turkey and other jurisdictions in which the Company may carry on business in the future; increased costs and risks related to the potential impact of climate change; changes in national and local government legislation, controls or regulations (including tax legislation) in  jurisdictions in which the Company does or may carry on business in the future; the costs and timing of construction and development of new deposits; risk of loss due to sabotage, protests and other civil disturbances; the impact of global liquidity and credit availability and the values of assets and liabilities based on projected future cash flows; risks arising from holding derivative instruments; and business opportunities that may be pursued by the Company.

For a more detailed discussion of such risks and other factors that may affect the Company’s ability to achieve the expectations set forth in the forward-looking statements contained in this news release, see the Company’s latest 40-F/Annual Information Form and Management’s Discussion and Analysis, each under the heading “Risk Factors” available on the SEDAR website at www.sedar.com or on EDGAR at www.sec.gov. The foregoing should be reviewed in conjunction with the information found in this news release.

The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. 

Cautionary Note to U.S. Investors

All Mineral Resource and Reserve estimates included in this Release or documents referenced in it have been prepared in accordance with Canadian National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”) and the Canadian Institute of Mining, Metallurgy and Petroleum (the “CIM”) – CIM Definition Standards on Mineral Resources and Mineral Reserves, adopted by the CIM Council, as amended (the “CIM Standards”). NI 43-101 is a rule developed by the Canadian Securities Administrators, which established standards for all public disclosure an issuer makes of scientific and technical information concerning mineral projects. The terms “Mineral Reserve”, “Proven Mineral Reserve” and “Probable Mineral Reserve” are Canadian mining terms as defined in accordance with NI 43-101 and the CIM Standards. 

The United States Securities and Exchange Commission (the “SEC”) permits mining companies, in their filings with the SEC, to disclose only those mineral deposits that a company can economically and legally extract or produce.  Alamos may use certain terms, such as “Measured Mineral Resources”, “Indicated Mineral Resources”, “Inferred Mineral Resources” and “Probable Mineral Reserves” which differ materially from the definitions in SEC Industry Guide 7  under the United States Securities Exchange Act of1934, as amended.

Investors are cautioned not to assume that all or any part of mineral deposits in these categories will ever be converted into Mineral Reserves. “Inferred Mineral Resources” have a great amount of uncertainty as to their existence, and great uncertainty as to their economic and legal feasibility. It cannot be assumed that all or any part of an Inferred Mineral Resource will ever be upgraded to a higher category. Under Canadian rules, estimates of Inferred Mineral Resources may not form the basis of feasibility or pre-feasibility studies, except in very limited circumstances. Disclosure of “contained ounces” in a Mineral Resource is permitted disclosure under Canadian regulations; however, the SEC normally only permits issuers to report mineralization that does not constitute “Mineral Reserves” by SEC standards as in place tonnage and grade without reference to unit measures.

The SEC has adopted final rules, effective February 25, 2019, to replace SEC Industry Guide 7 with new mining disclosure rules under sub-part 1300 of Regulation S-K of the U.S. Securities Act (the “SEC Modernization Rules”). The SEC Modernization Rules replace the historical property disclosure requirements included in SEC Industry Guide 7. As a result of the adoption of the SEC Modernization Rules, the SEC now recognizes estimates of “Measured Mineral Resources”, “Indicated Mineral Resources” and “Inferred Mineral Resources”. In addition, the SEC has amended its definitions of “Proven Mineral Reserves” and “Probable Mineral Reserves” to be substantially similar to international standards. The SEC Modernization Rules will become mandatory for U.S. reporting companies beginning with the first fiscal year commencing on or after January 1, 2021.

Cautionary non-GAAP Measures and Additional GAAP Measures

Note that for purposes of this section, GAAP refers to IFRS. The Company believes that investors use certain non-GAAP and additional GAAP measures as indicators to assess gold mining companies. They are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared with GAAP.

“Cash flow from operating activities before changes in non-cash working capital” is a non-GAAP performance measure that could provide an indication of the Company’s ability to generate cash flows from operations, and is calculated by adding back the change in non-cash working capital to “Cash provided by (used in) operating activities” as presented on the Company’s consolidated statements of cash flows. “Free cash flow” is a non-GAAP performance measure that is calculated as cash flows from operations net of cash flows invested in mineral property, plant and equipment and exploration and evaluation assets as presented on the Company’s consolidated statements of cash flows and that would provide an indication of the Company’s ability to generate cash flows from its mineral projects. “Mine site free cash flow” is a non-GAAP measure which includes cash flow from operating activities at, less capital expenditures at each mine site. Return on Equity is defined as Earnings from Continuing Operations divided by the average Total Equity for the current and previous year. “Mining cost per tonne of ore” and “Cost per tonne of ore” are non-GAAP performance measures that could provide an indication of the mining and processing efficiency and effectiveness of the mine. These measures are calculated by dividing the relevant mining and processing costs and total costs by the tonnes of ore processed in the period. “Cost per tonne of ore” is usually affected by operating efficiencies and waste-to-ore ratios in the period. “Total cash costs per ounce”, “all-in sustaining costs per ounce”, and “mine-site all-in sustaining costs” as used in this analysis are non-GAAP terms typically used by gold mining companies to assess the level of gross margin available to the Company by subtracting these costs from the unit price realized during the period. These non-GAAP terms are also used to assess the ability of a mining company to generate cash flow from operations. There may be some variation in the method of computation of these metrics as determined by the Company compared with other mining companies. In this context, “total cash costs” reflects mining and processing costs allocated from in-process and dore inventory associated and associated royalties with ounces of gold sold in the period. Total cash costs per ounce are exclusive of exploration costs. “All-in sustaining costs per ounce” include total cash costs, exploration, corporate and administrative, share based compensation and sustaining capital costs. “Mine-site all-in sustaining costs” include total cash costs, exploration, and sustaining capital costs for the mine-site, but exclude an allocation of corporate and administrative and share based compensation.

Additional GAAP measures that are presented on the face of the Company’s consolidated statements of comprehensive income and are not meant to be a substitute for other subtotals or totals presented in accordance with IFRS, but rather should be evaluated in conjunction with such IFRS measures. This includes “Earnings from operations”, which is intended to provide an indication of the Company’s operating performance, and represents the amount of earnings before net finance income/expense, foreign exchange gain/loss, other income/loss, and income tax expense. Non-GAAP and additional GAAP measures do not have a standardized meaning prescribed under IFRS and therefore may not be comparable to similar measures presented by other companies. A reconciliation of historical non-GAAP and additional GAAP measures are available at www.alamosgold.com



Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BMW, Zosano Pharma, Celsion, and Citigroup and Encourages Investors to Contact the Firm

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bayerische Motoren Werke AG (“BMW”) (Other OTC: BMWYY, BAMXF), Zosano Pharma Corporation (NASDAQ: ZSAN), Celsion Corporation (NASDAQ: CLSN), and Citigroup, Inc. (NYSE: C). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Bayerische
Motoren
Werke AG (“BMW”) (
Other
OTC: BMWYY, BAMXF)

Class Period: November 3, 2015 to September 24, 2020

Lead Plaintiff Deadline: December 28, 2020

On December 23, 2019, the Wall Street Journal reported that the SEC was probing BMW’s sales practices.

On this news, BMWYY ADRs fell $1.33 per ADR, or nearly 6.87%, to close at $18.02 per ADR on December 23, 2019. The same day, BAMXF ADRs fell $1.25, or 1.5%, to close at $80.60.

On September 24, 2020, the SEC announced a settlement agreement with BMW regarding the investigation. According to the SEC’s order, from January 2015 to March 2017, BMW US “used its demonstrator and service loaner programs to boost reported retail sales volume and meet internal targets, resulting in demonstrator and loaner vehicles accounting for over one quarter of BMW [US]’s reported retail sales in this period.” Additionally, the order found that BMW US, from 2015 to 2019, maintained a reserve of unreported retail vehicles sales – referred to internally as the “bank” – that it used to meet internal monthly sales targets regardless of when the actual sale occurred. The order also found that BMW improperly designated vehicles as demonstrators or loaners so they would be counted as sold when in actuality they were not. Without admitting to or denying the order’s findings, BMW agreed to a settlement to pay $18 million and cease and desist from future violations.

On this news, BMWYY ADRs fell $0.51 per ADR, or approximately 2.2%, to close at $23.07 per ADR on September 25, 2020. The same day, BAMXF ADRs fell $2.54, or about 3.5%, to close at $68.91.

The complaint, filed on October 27, 2020, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) BMW kept a “bank” of retail vehicle sales that it used to meet internal monthly sales targets regardless of when the sales actually occurred; (2) BMW artificially manipulated sales figures by having dealers register cars as sold when the cars were still in inventory; (3) as a result, BMW’s key operating metrics were inaccurate and misleading; and (4) as a result, defendants’ statements about BMW’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

For more information on the BMW class action go to: https://bespc.com/cases/BMW

Zosano
Pharma Corporation (NASDAQ: ZSAN)

Class Period: February 13, 2017 to September 30, 2020

Lead Plaintiff Deadline: December 28, 2020

Zosano is a clinical stage pharmaceutical company. Its lead product candidate is Qtrypta (M207), a formulation of zolmitriptan coated onto the Company’s microneedle patch. Its pivotal efficacy trial, called ZOTRIP, began in July 2016. In December 2019, Zosano submitted its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) seeking regulatory approval for Qtrypta.

On September 30, 2020, Zosano disclosed receipt of a discipline review letter (“DRL”) from the FDA regarding its NDA for Qtrypta and stated that approval was not likely. According to the Company’s press release, the FDA “raised questions regarding unexpected high plasma concentrations of zolmitriptan observed in five study subjects from two pharmacokinetic studies and how the data from these subjects affect the overall clinical pharmacology section of the application.” The FDA also “raised questions regarding differences in zolmitriptan exposures observed between subjects receiving different lots of Qtrypta in the company’s clinical trials.”

On this news, the Company’s share price fell $0.92, or 57%, to close at $0.70 per share on October 1, 2020.

On October 21, 2020, Zosano disclosed receipt of a Complete Response Letter (“CRL”) from the FDA. As a result of the previously identified deficiencies, the FDA recommended that Zosano conduct a repeat bioequivalence study between three of the lots used during development.

On this news, the Company’s share price fell $0.17, or 27%, to close at $0.04440 per share on October 21, 2020.

The complaint, filed on October 29, 2020, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the Company’s clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) that pharmacokinetic studies submitted in connection with the Company’s NDA included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) that, as a result of the foregoing differences among patient results, the FDA was reasonably likely to require further studies to support regulatory approval of Qtrypta; (4) that, as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, defendants’ public statements were materially false and misleading at all relevant times.

For more information on the Zosano class action go to: https://bespc.com/cases/ZSAN

Celsion
Corporation (NASDAQ: CLSN)

Class Period: November 2, 2015 to July 10, 2020

Lead Plaintiff Deadline: December 28, 2020

Celsion is an integrated development clinical stage oncology drug company that focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer.

Celsion’s lead product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin that is in Phase III clinical development for treating primary liver cancer.

In February 2014, Celsion announced that the U.S. Food and Drug Administration (“FDA”) had reviewed and provided clearance for the Company’s planned pivotal, double-blind, placebo-controlled Phase III trial of ThermoDox in combination with radio frequency ablation (“RFA”) in primary liver cancer, also known as hepatocellular carcinoma (“HCC”), called the “OPTIMA Study.” The trial design was purportedly based on a comprehensive analysis of data from the Company’s Phase III HEAT Study, which purportedly demonstrated that treatment with ThermoDox resulted in a 55% improvement in overall survival (“OS”) in a substantial number of HCC patients that received an optimized RFA treatment. 

On July 13, 2020, Celsion announced that “it ha[d] received a recommendation from the independent [DMC] to consider stopping the global Phase III OPTIMA Study of ThermoDox® in combination with [RFA] for the treatment of [HCC], or primary liver cancer.” According to the Company, “[t]he recommendation was made following the second pre-planned interim safety and efficacy analysis by the DMC on July 9, 2020,” which “found that the pre-specified boundary for stopping the trial for futility of 0.900 was crossed with an actual value of 0.903.”

On this news, Celsion’s stock price fell $2.29 per share, or 63.97%, to close at $1.29 per share on July 13, 2020.

The complaint, filed on October 29, 2020, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) defendants had significantly overstated the efficacy of ThermoDox; (ii) the foregoing significantly diminished the approval and commercialization prospects for ThermoDox; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

For more information on the Celsion class action go to: https://bespc.com/cases/CLSN

Citigroup, Inc. (NYSE: C)

Class Period: January 15, 2016 to October 12, 2020

Lead Plaintiff Deadline: December 29, 2020

The Class Period begins on February 25, 2017, following the Company’s submission of its 2016 Annual Report to the SEC. In that filing, and throughout the Class Period, Citi assured investors that there were no significant deficiencies or material weaknesses in the Company’s internal controls. When faced with periodic regulatory penalties for noncompliance, the Company continued to assure investors that the specific deficiencies at issue were being remediated promptly and that internal controls and regulatory compliance were a top priority at Citi. In particular, Citi assured investors that it satisfied all regulatory requirements and maintained adequate internal controls, data governance, compliance risk management, and enterprise risk management.

In reality, during the Class Period and unbeknownst to investors, Citi’s internal controls and risk management capabilities suffered from “serious” and “longstanding” inadequacies that exposed the Company to massive regulatory penalties and will cost significantly more than $1 billion to remediate. Specific control failures about which Citi executives were warned remained unresolved for years and the Company’s culture of non-compliance was so widespread that Citi’s CEO, Defendant Michael Corbat, exhorted employees in an internal memo that regulatory compliance required more than “checking boxes.”

The truth began to emerge on September 14, 2020, when reports surfaced that regulators were preparing to reprimand Citi for failing to improve its risk-management systems.

That disclosure caused the price of Citi’s stock to decline $2.85 per share, from $51.00 to $48.15, erasing $5.91 billion in shareholder value.

After the market closed on September 14, 2020, an internal memo sent to Citi employees revealed for the first time the Company’s disregard for adequate internal controls and regulatory compliance.

As a result, the price of Citi’s stock declined an additional $3.34 per share, from $48.15 to $44.81, erasing $6.93 billion in shareholder value.

Then, on October 13, 2020, Citi reported earnings for the third quarter of 2020, and disclosed that the Company’s expenses increased during the third quarter by 5%, to $11 billion, due to an increase in costs including a $400 million fine, investments in infrastructure, and other remediation costs related to control deficiencies.

These disclosures caused Citi’s stock price to decline by $2.20 per share, from $45.88 to $43.68, erasing $4.57 billion in shareholder value.

For more information on the Citigroup class action go to: https://bespc.com/cases/C

About
Bragar
Eagel
& Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
(212) 355-4648
[email protected]
www.bespc.com



Noront Resources Announces Director Resignation

TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) — Noront Resources Ltd. (“Noront” or the “Company”) (TSX Venture: NOT) announced today that Gregory Honig, Director of Origination, Canada, Resource Capital Funds (“RCF”) has resigned from the Company’s Board of Directors.   

Mr. Honig’s resignation follows the recently announced agreement that will result in the sale of Resource Capital Fund V L.P.’s beneficial equity and debt interests in Noront Resources to Wyloo Metals Pty Ltd.

Noront Chairman Paul Parisotto said, “On behalf of the Noront Board of Directors and Management team, I would like to thank Mr. Honig for his service and extend our appreciation to RCF which was a cornerstone investor in Noront for many years. Their confidence in us and their support was invaluable in helping us advance our projects in the Ring of Fire.”


About Noront Resources


Noront Resources Ltd. is focused on development of its high-grade Eagle’s Nest nickel, copper, platinum and palladium deposit and the world class chromite deposits including Blackbird, Black Thor, and Big Daddy, all of which are located in the James Bay Lowlands of Ontario in an emerging metals camp known as the Ring of Fire. www.norontresources.com

For more information:

Janice Mandel
[email protected]
(647) 300-3853



Oppenheimer Holdings Inc. Declares Special Dividend

PR Newswire

NEW YORK, Dec. 9, 2020 /PRNewswire/ – Oppenheimer Holdings Inc. (“OPY”) today announced that its Board of Directors has declared a special cash dividend on OPY Class A non-voting and Class B voting common stock of $1.00 per share, payable December 30, 2020, to shareholders of record as of the close of business on December 23, 2020. The aggregate payment will be approximately $12.4 million. The special dividend will be funded through existing cash.

Albert G. Lowenthal, Chairman and Chief Officer, commented: “We are pleased to recognize the year’s operating results and our improved financial position through the announcement of a special dividend of $1.00 per share. This will reward shareholders for their loyalty to the business and prospects of Oppenheimer. We remain optimistic about the future and continue to dedicate ourselves to continued growth.”

Company Information

Oppenheimer Holdings Inc., through its operating subsidiaries, is a leading middle market investment bank and full service broker-dealer that is engaged in a broad range of activities in the financial services industry, including retail securities brokerage, institutional sales and trading, investment banking (corporate and public finance), equity and fixed income research, market-making, trust services, and investment advisory and asset management services. With roots tracing back to 1881, the Company is headquartered in New York and has 93 retail branch offices in the United States and has institutional businesses located in London, Tel Aviv, and Hong Kong.

Forward-Looking Statements

Certain statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. OPY cautions that a number of important factors could cause OPY’s actual future results and other future circumstances to differ materially from those expressed in any forward-looking statements. Such factors include, but are not limited to the factors identified in “Factors Affecting ‘Forward-Looking Statements'” and Part 1A—”Risk Factors” in OPY’s Annual Report on Form 10-K for the year ended December 31, 2019, and OPY’s Quarterly Reports for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020. OPY does not undertake any obligation to release publicly any revisions to forward-looking statements made by it to reflect events or circumstances occurring after the date hereof or the occurrence of unanticipated events.

Cision View original content:http://www.prnewswire.com/news-releases/oppenheimer-holdings-inc-declares-special-dividend-301189893.html

SOURCE Oppenheimer Holdings Inc.

Greif Reports Fourth Quarter and Fiscal 2020 Results

PR Newswire

DELAWARE, Ohio, Dec. 9, 2020 /PRNewswire/ — Greif, Inc. (NYSE: GEF, GEF.B), a world leader in industrial packaging products and services, today announced fourth quarter and fiscal 2020 results.

Fourth Quarter Highlights Include (all results compared to the fourth quarter 2019 unless otherwise noted):

  • Net income of $44.4 million or $0.74 per diluted Class A share decreased compared to net income of $65.0 million or $1.09 per diluted Class A share. Net income, excluding the impact of adjustments(1), of $46.4 million or $0.78 per diluted Class A share decreased compared to net income, excluding the impact of adjustments, of $73.4 million or $1.24 per diluted Class A share. Adjusted EBITDA(2) decreased by $32.3 million to $154.5 million.
  • Net cash provided by operating activities increased by $5.0 million to $200.4 million. Adjusted free cash flow(3) increased by $23.7 million to $173.9 million.
  • Awarded a Gold Rating in sustainability performance for the third consecutive year by EcoVadis.

Fiscal Year Highlights Include (all results compared to the fiscal year 2019 unless otherwise noted):

  • Net income of $108.8 million or $1.83 per diluted Class A share decreased compared to net income of $171.0 million or $2.89 per diluted Class A share. Net income, excluding the impact of adjustments, of $190.9 million or $3.22 per diluted Class A share decreased compared to net income, excluding the impact of adjustments, of $234.0 million or $3.96 per diluted Class A share. Adjusted EBITDA decreased by $16.3 million to $642.6 million.
  • Net cash provided by operating activities increased by $65.2 million to $454.7 million. Adjusted free cash flow increased by $78.4 million to $346.2 million.
  • Reduced net debt(4) by $293.5 million since October 31, 2019 and paid $104.3 million in dividends to stockholders.

Pete Watson, Greif’s President and Chief Executive Officer, commented:

“I am very proud of the commitment displayed by the Greif team to adapt and manage the challenges presented by the COVID-19 pandemic this past year,” said Pete Watson, Greif’s President and Chief Executive Officer. “Through our focus on customer service excellence and disciplined operational execution, the team delivered solid financial results, strong cash flow and significant debt reduction in a challenging operating environment. I am particularly pleased with our team’s results in reducing working capital, which created a strong source of cash in the fiscal fourth quarter that helped drive our fiscal 2020 adjusted free cash flow well higher than our previously announced forecast.

Looking ahead, while downstream industries are gradually ramping back up, there remains lingering uncertainty in the global economy. We are committed to managing those areas within our control to navigate successfully through these uncertainties. Greif is well positioned to benefit as the economy further recovers.”

(1)

Adjustments that are excluded from net income before adjustments and from earnings per diluted Class A share before adjustments are gain or loss on disposal of properties, plants, equipment and business, net, restructuring charges, acquisition-related costs, non-cash asset impairment charges, incremental COVID-19 costs, net, debt extinguishment charges, non-cash pension settlement income and tax net expense (benefit) resulting from the Tax Cuts and Jobs Act (“Tax Reform Act”).

(2)

Adjusted EBITDA is defined as net income, plus interest expense, net, plus debt extinguishment charges, plus income tax expense, plus depreciation, depletion and amortization expense, plus restructuring charges, plus acquisition-related costs, plus non-cash asset impairment charges, plus incremental COVID-19 costs, net, plus non-cash pension settlement (income) charges, less (gain) loss on disposal of properties, plants, equipment and businesses, net.

(3)

Adjusted free cash flow is defined as net cash provided by (used in) operating activities, less cash paid for purchases of properties, plants and equipment, plus cash paid for acquisition-related costs, plus cash paid for debt issuance costs, plus cash paid for incremental COVID-19 costs, net, plus cash paid for acquisition-related Enterprise Resource Planning (ERP) systems.

(4)

Net debt is defined as total debt less cash and cash equivalents.

Note: A reconciliation of the differences between all non-GAAP financial measures used in this release with the most directly comparable GAAP financial measures is included in the financial schedules that are a part of this release. These non-GAAP financial measures are intended to supplement and should be read together with our financial results. They should not be considered an alternative or substitute for, and should not be considered superior to, our reported financial results. Accordingly, users of this financial information should not place undue reliance on these non-GAAP financial measures.

 

Customer Service

The Company’s consolidated CSI(5) score was 92.9 during the fiscal fourth quarter 2020 and reached a record high of 93.0 on a trailing four quarter basis. Our long term objective is for each business segment to achieve a CSI score of 95.0 or greater.

CSI for the Rigid Industrial Packaging & Services segment was 93.7, which was approximately 4 percent higher compared to the prior year quarter. CSI for the Flexible Products & Services segment was 86.4, which was approximately 9 percent lower compared to the prior year quarter as a result of COVID-19 related delays to product shipments due to staffing constraints. CSI for the Paper Packaging & Services segment was 91.0, which was approximately flat to the prior year quarter.

Additionally, we completed our tenth NPS(6) survey and achieved our best ever score of 67.0. Our latest NPS result was approximately 10% better than our wave nine survey conducted in late 2019 and a 72% improvement from the initial wave one conducted in late 2015. We continue to leverage the increased customer interactions that accompany each survey into enhanced service offerings for our customers and better strategic insight into their business needs.

Liquidity and Balance Sheet

As of October 31, 2020, the Company had $538.1 million of available borrowing capacity(7) within its $800.0 million revolving credit facility. Subsequent to October 31, 2020, the Company entered into a delayed draw term loan with the intent to utilize the proceeds to pay down the Company’s Euro 200 million 7.375% senior notes at maturity in July of 2021. Based on the provisions of the applicable loan documents and a series of forward interest rate swaps entered into by the Company, if this term loan was drawn down today, the interest rate would initially be approximately 2.5% per annum. Other than the Euro 200 million senior notes, the Company has no other sizable debt maturities due until 2024.

For the year ended October 31, 2020, the Company’s adjusted free cash flow was $346.2 million compared to $267.8 million for the year ended October 31, 2019. The increase in adjusted free cash flow was primarily attributable to $56.1 million of cash provided by operating working capital as a result of management initiatives and tight market conditions, particularly in the Paper Packaging & Services segment.

Segment Results (all results compared to the fourth quarter of 2019 unless otherwise noted)

Net sales are impacted mainly by the volume of primary products(8) sold, selling prices, product mix and the impact of changes in foreign currencies against the U.S. Dollar. The table below shows the percentage impact of each of these items on net sales for our primary products for the fourth quarter of 2020 as compared to the prior year quarter for the business segments with manufacturing operations.



Net Sales Impact – Primary Products


Rigid Industrial



Packaging & 

Services


Paper Packaging &
Services


Flexible Products
& Services

%

%

%


Currency Translation

(0.4)

%

2.7

%


Volume

(2.6)

%

8.0

%

(0.2)

%


Selling Prices and Product Mix

(3.4)

%

(2.4)

%

1.7

%


Total Impact of Primary Products

(6.4)

%

5.6

%

4.2

%

Rigid Industrial Packaging & Services

Net sales decreased by $39.9 million to $579.1 million. Net sales excluding foreign currency translation decreased by $38.9 million due primarily to lower volumes and lower average sale prices driven by contractual price adjustment mechanisms related to raw material price decreases.

Gross profit decreased by $0.2 million to $113.8 million. The change in gross profit was primarily due to the same factors that impacted net sales, partially offset by lower priced raw materials.

Operating profit decreased by $0.9 million to $54.1 million. Adjusted EBITDA decreased by $4.2 million to $65.3 million primarily due to the same factors that impacted gross profit and higher segment SG&A expense, partially offset by the segment receiving a smaller portion of allocated corporate costs. The segment’s SG&A expense in the prior year quarter included a one-time Brazilian tax recovery of approximately $7.0 million, which was previously disclosed.

Paper Packaging & Services

Net sales decreased by $32.8 million to $502.3 million primarily due to approximately $58.0 million of prior year net sales attributable to the divested Consumer Packaging Group business, as well as lower published containerboard and boxboard prices, partially offset by higher volumes.

Gross profit decreased by $29.7 million to $98.8 million. The change in gross profit was primarily due to the same factors that impacted net sales and higher old corrugated container input costs, partially offset by lower manufacturing costs.

Operating profit decreased by $25.0 million to $30.7 million. Adjusted EBITDA decreased by $31.3 million to $77.4 million primarily due to the same factors that impacted gross profit and the segment receiving a greater portion of allocated corporate costs, partially offset by a reduction in the segment’s SG&A expense that was, in part, attributable to synergy realizations.

Flexible Products & Services

Net sales increased by $2.3 million to $73.2 million. Net sales excluding foreign currency translation increased by $0.4 million due primarily to due to higher average sale prices, partially offset by lower volumes.

Gross profit increased by $2.8 million to $17.0 million. The change in gross profit was primarily due to the same factors that impacted net sales and lower priced raw materials.

Operating profit increased by $1.7 million to $4.8 million. Adjusted EBITDA increased by $3.0 million to $8.8 million primarily due to the same factors that impacted gross profit.

Land Management

Net sales decreased by $0.4 million to $6.7 million.

Operating profit increased by $0.3 million to $2.2 million. Adjusted EBITDA increased by $0.2 million to $3.0 million.

Tax Summary

During the fourth quarter, the Company recorded an income tax rate of 27.9 percent and a tax rate excluding the impact of adjustments of 26.1 percent. As previously disclosed, the application of FIN 18 often causes fluctuations in our quarterly effective tax rates. For the full year, the Company recorded an income tax rate of 34.0 percent and a tax rate excluding the impact of adjustments of 27.0 percent. 

Dividend Summary

On December 8, 2020, the Board of Directors declared quarterly cash dividends of $0.44 per share of Class A Common Stock and $0.65 per share of Class B Common Stock. Dividends are payable on January 1, 2021, to stockholders of record at the close of business on December 18, 2020.

Company Outlook

The Company is introducing a quarterly outlook given the continued market unpredictability caused by the COVID-19 pandemic. The Company will revert to annual guidance once the duration and economic impact of the pandemic is better understood.


(in millions, except per share amounts)


Q1 Fiscal 2021
Outlook

Class A earnings per share before adjustments (9)

$0.48 – $0.58

 

(5)

Customer satisfaction index (CSI) tracks a variety of internal metrics designed to enhance the customer experience in dealing with Greif.

(6)

Net Promoter Score (NPS) is derived from a survey conducted by a third party that measures how likely a customer is to recommend Greif as a business partner. NPS scores are calculated by subtracting the percentage of detractors a business has from the percentage of its promoters.

(7)

Available borrowing capacity is determined by the lesser of the available capacity on the Company’s secured revolving credit facility or the amount which could be borrowed without causing the Company’s leverage ratio to exceed 4.5.

(8)

Primary products are manufactured steel, plastic and fibre drums; new and reconditioned intermediate bulk containers; linerboard, containerboard, corrugated sheets and corrugated containers, boxboard and tube and core products; and 1&2 loop and 4 loop flexible intermediate bulk containers.

(9)

Q1 2021 Class A earnings per share guidance on a GAAP basis is not provided in this release due to the potential for one or more of the following, the timing and magnitude of which we are unable to reliably forecast: gains or losses on the disposal of businesses, timberland or properties, plants and equipment, net; non-cash asset impairment charges due to unanticipated changes in the business; restructuring-related activities; non-cash pension settlement charges; or acquisition-related costs, and the income tax effects of these items and other income tax-related events. No reconciliation of the Q1 fiscal year 2021 Class A earnings per share before adjustments, a non-GAAP financial measure which exclude gains and losses on the disposal of businesses, timberland and properties, plants and equipment, non-cash pension settlement charges, acquisition-related costs, restructuring, and impairment charges is included in this release because, due to the high variability and difficulty in making accurate forecasts and projections of some of the excluded information, together with some of the excluded information not being ascertainable or accessible, we are unable to quantify certain amounts that would be required to be included in the most directly comparable GAAP financial measure without unreasonable efforts.

Conference Call

The Company will host a conference call to discuss the fourth quarter of 2020 results on December 10, 2020, at 8:30 a.m. Eastern Time (ET). Participants may access the call using the following online registration link: http://www.directeventreg.com/registration/event/8795459. Registrants will receive a confirmation email containing dial in details and a unique conference call code for entry. Phone lines will open at 8:00 a.m. ET. The conference call will also be available through a live webcast, including slides, which can be accessed at http://investor.greif.com by clicking on the Events and Presentations tab and searching under the events calendar. A replay of the conference call will be available on the Company’s website approximately two hours following the call.

About Greif

Greif is a global leader in industrial packaging products and services and is pursuing its vision: in industrial packaging, be the best performing customer service company in the world. The Company produces steel, plastic and fibre drums, intermediate bulk containers, reconditioned containers, flexible products, containerboard, uncoated recycled paperboard, coated recycled paperboard, tubes and cores and a diverse mix of specialty products. The Company also manufactures packaging accessories and provides filling, packaging and other services for a wide range of industries. In addition, Greif manages timber properties in the southeastern United States. The Company is strategically positioned in over 40 countries to serve global as well as regional customers. Additional information is on the Company’s website at www.greif.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “aspiration,” “objective,” “project,” “believe,” “continue,” “on track” or “target” or the negative thereof and similar expressions, among others, identify forward-looking statements. All forward-looking statements are based on assumptions, expectations and other information currently available to management. Such forward-looking statements are subject to certain risks and uncertainties that could cause the Company’s actual results to differ materially from those forecasted, projected or anticipated, whether expressed or implied. The most significant of these risks and uncertainties are described in Part I of the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2020. The Company undertakes no obligation to update or revise any forward-looking statements.

Although the Company believes that the expectations reflected in forward-looking statements have a reasonable basis, the Company can give no assurance that these expectations will prove to be correct. Forward-looking statements are subject to risks and uncertainties that could cause the Company’s actual results to differ materially from those forecasted, projected or anticipated, whether expressed in or implied by the statements. Such risks and uncertainties that might cause a difference include, but are not limited to, the following: (i) historically, our business has been sensitive to changes in general economic or business conditions, (ii) our global operations subject us to currency exchange and political risks that could adversely affect our results of operations, (iii) the COVID-19 pandemic could have a material adverse effect on our business, financial condition, results of operations and cash flows, (iv) the current and future challenging global economy and disruption and volatility of the financial and credit markets may adversely affect our business, (v) the continuing consolidation of our customer base and suppliers may intensify pricing pressure, (vi) we operate in highly competitive industries, (vii) our business is sensitive to changes in industry demands, (viii) raw material and energy price fluctuations and shortages may adversely impact our manufacturing operations and costs, (ix) the frequency and volume of our timber and timberland sales will impact our financial performance, (x) we may not successfully implement our business strategies, including achieving our growth objectives, (xi) we may encounter difficulties or liabilities arising from acquisitions or divestitures, (xii) the acquisition of Caraustar Industries, Inc. and its subsidiaries subjects us to various risks and uncertainties, (xiii) we may incur additional restructuring costs and there is no guarantee that our efforts to reduce costs will be successful, (xiv) several operations are conducted by joint ventures that we cannot operate solely for our benefit, (xv) certain of the agreements that govern our joint ventures provide our partners with put or call options, (xvi) our ability to attract, develop and retain talented and qualified employees, managers and executives is critical to our success, (xvii) our business may be adversely impacted by work stoppages and other labor relations matters, (xviii) we may be subject to losses that might not be covered in whole or in part by existing insurance reserves or insurance coverage and general insurance premium and deductible increases, (xix) our business depends on the uninterrupted operations of our facilities, systems and business functions, including our information technology and other business systems, (xx) a security breach of customer, employee, supplier or Company information may have a material adverse effect on our business, financial condition, results of operations and cash flows, (xxi) changes in U.S. generally accepted accounting principles (GAAP) and SEC rules and regulations concerning the maintenance of effective internal controls could materially impact our reported financial results, (xxii) we could be subject to changes to our tax rates, the adoption of new U.S. or foreign tax legislation or exposure to additional tax liabilities, (xxiii) full realization of our deferred tax assets may be affected by a number of factors, (xxiv) our level of indebtedness could adversely affect our liquidity, limit our flexibility in responding to business opportunities, and increase our vulnerability to adverse changes in economic and industry conditions, (xxv) we have a significant amount of goodwill and long-lived assets which, if impaired in the future, would adversely impact our results of operations, (xxvi) our pension and postretirement plans are underfunded and will require future cash contributions and our required future cash contributions could be higher than we expect, each of which could have a material adverse effect on our financial condition and liquidity, (xxvii) legislation/regulation related to environmental and health and safety matters and corporate social responsibility could negatively impact our operations and financial performance, (xxviii) product liability claims and other legal proceedings could adversely affect our operations and financial performance, (xxix) we may incur fines or penalties, damage to our reputation or other adverse consequences if our employees, agents or business partners violate, or are alleged to have violated, anti-bribery, competition or other laws, (xxx) changing climate, climate change regulations and greenhouse gas effects may adversely affect our operations and financial performance.  The risks described above are not all-inclusive, and given these and other possible risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. For a detailed discussion of the most significant risks and uncertainties that could cause our actual results to differ materially from those forecasted, projected or anticipated, see “Risk Factors” in Part I, Item 1A of our most recently filed Form 10-K and our other filings with the Securities and Exchange Commission. All forward-looking statements made in this news release are expressly qualified in their entirety by reference to such risk factors. Except to the limited extent required by applicable law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 


GREIF, INC. AND SUBSIDIARY COMPANIES


CONDENSED CONSOLIDATED STATEMENTS OF INCOME

UNAUDITED


Three Months Ended
October 31,


Twelve Months Ended
October 31,


(in millions, except per share amounts)


2020


2019


2020


2019

Net sales

$

1,161.3

$

1,232.1

$

4,515.0

$

4,595.0

Cost of products sold

929.6

973.1

3,600.3

3,635.1

Gross profit

231.7

259.0

914.7

959.9

Selling, general and administrative expenses

139.1

130.4

516.0

507.4

Restructuring charges

11.9

5.8

38.7

26.1

Acquisition-related costs

3.5

7.5

17.0

29.7

Non-cash asset impairment charges

1.6

5.7

18.5

7.8

(Gain) loss on disposal of properties, plants and equipment,
net

(17.1)

(6.8)

(19.2)

(13.9)

(Gain) loss on disposal of businesses, net

0.9

0.7

38.8

3.7

Operating profit

91.8

115.7

304.9

399.1

Interest expense, net

26.0

32.4

115.8

112.5

Non-cash pension settlement charges

0.4

0.3

Debt extinguishment charges

22.0

Other (income) expense, net

(0.8)

1.6

2.7

2.6

Income before income tax expense and equity earnings
of unconsolidated affiliates, net

66.2

81.7

186.1

262.0

Income tax expense

18.5

12.4

63.3

70.7

Equity earnings of unconsolidated affiliates, net of tax

(0.3)

(0.5)

(1.5)

(2.9)

Net income

48.0

69.8

124.3

194.2

Net income attributable to noncontrolling interests

(3.6)

(4.8)

(15.5)

(23.2)

Net income attributable to Greif, Inc.

$

44.4

$

65.0

$

108.8

$

171.0


Basic earnings per share attributable to Greif, Inc.
common shareholders:

Class A common stock

$

0.74

$

1.09

$

1.83

$

2.89

Class B common stock

$

1.12

$

1.65

$

2.74

$

4.33


Diluted earnings per share attributable to Greif, Inc.
common shareholders:

Class A common stock

$

0.74

$

1.09

$

1.83

$

2.89

Class B common stock

$

1.12

$

1.65

$

2.74

$

4.33


Shares used to calculate basic earnings per share
attributable to Greif, Inc. common shareholders:

Class A common stock

26.4

26.3

26.4

26.2

Class B common stock

22.0

22.0

22.0

22.0


Shares used to calculate diluted earnings per share
attributable to Greif, Inc. common shareholders:

Class A common stock

26.5

26.4

26.4

26.2

Class B common stock

22.0

22.0

22.0

22.0

 


GREIF, INC. AND SUBSIDIARY COMPANIES


CONDENSED CONSOLIDATED BALANCE SHEETS 

UNAUDITED


(in millions)


October 31, 2020


October 31, 2019


ASSETS

CURRENT ASSETS

Cash and cash equivalents

$

105.9

$

77.3

Trade accounts receivable

636.6

664.2

Inventories

293.6

358.2

Assets held by special purpose entities

50.9

Other current assets

215.8

149.3

1,302.8

1,249.0

LONG-TERM ASSETS

Goodwill

1,518.4

1,517.8

Intangible assets

715.3

776.5

Assets held by special purpose entities

50.9

Operating lease assets

307.5

Other long-term assets

140.0

142.2

2,681.2

2,487.4

PROPERTIES, PLANTS AND EQUIPMENT

1,526.9

1,690.3

$

5,510.9

$

5,426.7


LIABILITIES AND EQUITY

CURRENT LIABILITIES

Accounts payable

$

450.7

$

435.2

Short-term borrowings

28.4

9.2

Current portion of long-term debt

123.1

83.7

Current portion of operating lease liabilities

52.3

Current portion of liabilities held by special purpose entities

43.3

Other current liabilities

302.3

297.3

1,000.1

825.4

LONG-TERM LIABILITIES

Long-term debt

2,335.5

2,659.0

Liabilities held by special purpose entities

43.3

Operating lease liabilities

257.7

Other long-term liabilities

696.9

686.6

3,290.1

3,388.9

REDEEMABLE NONCONTROLLING INTERESTS

20.0

21.3

EQUITY

Total Greif, Inc. equity 

1,152.2

1,133.1

Noncontrolling interests

48.5

58.0

1,200.7

1,191.1

$

5,510.9

$

5,426.7

 


GREIF, INC. AND SUBSIDIARY COMPANIES


CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

UNAUDITED


Three Months Ended
October 31,


Twelve Months Ended
October 31,


(in millions)


2020


2019


2020


2019

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income

$

48.0

$

69.8

$

124.3

$

194.2

Depreciation, depletion and amortization

60.1

59.3

242.5

206.1

Asset impairments

1.6

5.7

18.5

7.8

Non-cash lease expense

14.4

57.4

Deferred income tax expense

22.0

14.8

16.7

2.1

Other non-cash adjustments to net income

(21.0)

(10.1)

12.7

10.2

Operating working capital changes

43.3

71.6

56.1

19.1

Deferred purchase price on sold receivables

(6.9)

Operating leases

(12.5)

(54.9)

Increase (decrease) in cash from changes in other assets and
liabilities

44.5

(15.7)

(18.6)

(43.1)

Net cash provided by operating activities

200.4

195.4

454.7

389.5

CASH FLOWS FROM INVESTING ACTIVITIES:

Acquisitions of businesses, net of cash acquired

(1,857.9)

Purchases of properties, plants and equipment

(32.6)

(53.0)

(131.4)

(156.8)

Purchases of and investments in timber properties

(1.4)

(1.3)

(5.4)

(5.4)

Purchases of equity method investments

(3.6)

Proceeds from the sale of properties, plants and equipment,
businesses, timberland and other assets

23.6

12.5

114.3

30.2

Proceeds on insurance recoveries

0.4

0.9

0.6

Net cash used in investing activities

(10.4)

(41.4)

(25.2)

(1,989.3)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from (payments on) debt, net

(152.3)

(125.8)

(287.6)

1,751.1

Dividends paid to Greif, Inc. shareholders

(26.1)

(26.1)

(104.3)

(104.0)

Payments for extinguishment and issuance of debt

(44.1)

Other

(1.3)

(13.4)

(19.5)

Net cash provided by (used for) financing activities

(179.7)

(151.9)

(405.3)

1,583.5

Effects of exchange rates on cash

(2.9)

(0.6)

4.4

(0.6)

Net increase (decrease) in cash and cash equivalents

7.4

1.5

28.6

(16.9)

Cash and cash equivalents, beginning of period

98.5

75.8

77.3

94.2

Cash and cash equivalents, end of period

$

105.9

$

77.3

$

105.9

$

77.3

 


GREIF, INC. AND SUBSIDIARY COMPANIES


FINANCIAL HIGHLIGHTS BY SEGMENT

UNAUDITED


Three Months Ended
October 31,


Twelve Months Ended
October 31,


(in millions)


2020


2019


2020


2019


Net sales:

Rigid Industrial Packaging & Services

$

579.1

$

619.0

$

2,298.9

$

2,490.6

Paper Packaging & Services

502.3

535.1

1,916.9

1,780.0

Flexible Products & Services

73.2

70.9

272.9

297.5

Land Management

6.7

7.1

26.3

26.9

Total net sales

$

1,161.3

$

1,232.1

$

4,515.0

$

4,595.0


Gross profit:

Rigid Industrial Packaging & Services

$

113.8

$

114.0

$

465.3

$

460.1

Paper Packaging & Services

98.8

128.5

382.7

425.4

Flexible Products & Services

17.0

14.2

57.5

64.2

Land Management

2.1

2.3

9.2

10.2

Total gross profit

$

231.7

$

259.0

$

914.7

$

959.9


Operating profit:

Rigid Industrial Packaging & Services

$

54.1

$

55.0

$

209.9

$

179.6

Paper Packaging & Services

30.7

55.7

71.0

184.3

Flexible Products & Services

4.8

3.1

15.5

25.3

Land Management

2.2

1.9

8.5

9.9

Total operating profit

$

91.8

$

115.7

$

304.9

$

399.1


EBITDA

(10)

:

Rigid Industrial Packaging & Services

$

73.6

$

71.6

$

284.6

$

251.6

Paper Packaging & Services

68.5

94.4

225.9

307.0

Flexible Products & Services

6.9

4.9

22.4

32.7

Land Management

3.6

3.0

13.0

14.2

Total EBITDA

$

152.6

$

173.9

$

545.9

$

605.5


Adjusted EBITDA(11):

Rigid Industrial Packaging & Services

$

65.3

$

69.5

$

297.5

$

269.9

Paper Packaging & Services

77.4

108.7

306.4

348.3

Flexible Products & Services

8.8

5.8

26.8

28.6

Land Management

3.0

2.8

11.9

12.1

Total Adjusted EBITDA

$

154.5

$

186.8

$

642.6

$

658.9


(10) EBITDA is defined as net income, plus interest expense, net, plus debt extinguishment charges, plus income tax expense, plus depreciation, depletion and amortization. However, because the Company does not calculate net income by segment, this table calculates EBITDA by segment with reference to operating profit by segment, which, as demonstrated in the table of Consolidated EBITDA, is another method to achieve the same result. See the reconciliations in the table of Segment EBITDA.


(11) Adjusted EBITDA is defined as net income, plus interest expense, net, plus debt extinguishment charges, plus income tax expense, plus depreciation, depletion and amortization expense, plus restructuring charges, plus acquisition-related costs, plus non-cash impairment charges, plus incremental COVID-19 costs, net, plus non-cash pension settlement (income) charges, less (gain) loss on disposal of properties, plants, equipment and businesses, net.

 


GREIF, INC. AND SUBSIDIARY COMPANIES


GAAP TO NON-GAAP RECONCILIATION


CONSOLIDATED ADJUSTED EBITDA

UNAUDITED


Three Months Ended
October 31,


Twelve Months Ended
October 31,


(in millions)


2020


2019


2020


2019

Net income

$

48.0

$

69.8

$

124.3

$

194.2

Plus: Interest expense, net

26.0

32.4

115.8

112.5

Plus: Debt extinguishment charges

22.0

Plus: Income tax expense

18.5

12.4

63.3

70.7

Plus: Depreciation, depletion and amortization expense

60.1

59.3

242.5

206.1

EBITDA

$

152.6

$

173.9

$

545.9

$

605.5

Net income

$

48.0

$

69.8

$

124.3

$

194.2

Plus: Interest expense, net

26.0

32.4

115.8

112.5

Plus: Debt extinguishment charges

22.0

Plus: Income tax expense

18.5

12.4

63.3

70.7

Plus: Non-cash pension settlement charges

0.4

0.3

Plus: Other (income) expense, net

(0.8)

1.6

2.7

2.6

Plus: Equity earnings of unconsolidated affiliates, net of tax

(0.3)

(0.5)

(1.5)

(2.9)

Operating profit

91.8

115.7

304.9

399.1

Less: Other (income) expense, net

(0.8)

1.6

2.7

2.6

Less: Non-cash pension settlement charges

0.4

0.3

Less: Equity earnings of unconsolidated affiliates, net of tax

(0.3)

(0.5)

(1.5)

(2.9)

Plus: Depreciation, depletion and amortization expense

60.1

59.3

242.5

206.1

EBITDA

$

152.6

$

173.9

$

545.9

$

605.5

Plus: Restructuring charges

$

11.9

$

5.8

$

38.7

$

26.1

Plus: Acquisition-related costs

3.5

7.5

17.0

29.7

Plus: Non-cash asset impairment charges

1.6

5.7

18.5

7.8

Plus: Non-cash pension settlement charges

0.4

0.3

Plus: Incremental COVID-19 costs, net(12)

0.7

2.6

Less: (Gain) loss on disposal of properties, plants,
equipment, and businesses, net

(16.2)

(6.1)

19.6

(10.2)

Adjusted EBITDA

$

154.5

$

186.8

$

642.6

$

658.9


(12) Incremental COVID-19 costs, net includes costs directly attributable to COVID-19 such as costs incurred for incremental cleaning and sanitation efforts and employee safety measures, offset by economic relief received from foreign governments.

 


GREIF, INC. AND SUBSIDIARY COMPANIES


GAAP TO NON-GAAP RECONCILIATION


SEGMENT ADJUSTED EBITDA

(13)   

UNAUDITED


Three Months Ended
October 31,


Twelve Months Ended
October 31,


(in millions)


2020


2019


2020


2019


Rigid Industrial Packaging & Services

Operating profit

$

54.1

$

55.0

$

209.9

$

179.6

Less: Other expense, net

0.2

3.2

5.3

7.2

Less: Non-cash pension settlement charges

0.4

0.4

Less: Equity earnings of unconsolidated affiliates, net of tax

(0.3)

(0.5)

(1.5)

(2.9)

Plus: Depreciation and amortization expense

19.8

19.3

78.9

76.3

EBITDA

$

73.6

$

71.6

$

284.6

$

251.6

Plus: Restructuring charges

6.6

3.8

26.0

18.8

Plus: Acquisition-related costs

0.2

0.6

Plus: Non-cash asset impairment charges

1.5

0.6

5.1

2.7

Plus: Non-cash pension settlement charges

0.4

0.4

Plus: Incremental COVID-19 costs, net

(0.2)

0.1

Less: (Gain) loss on disposal of properties, plants, equipment, and
businesses, net

(16.6)

(6.7)

(18.7)

(3.8)

Adjusted EBITDA

$

65.3

$

69.5

$

297.5

$

269.9


Paper Packaging & Services

Operating profit

$

30.7

$

55.7

$

71.0

$

184.3

Less: Other income, net

(0.1)

(1.3)

(1.3)

(3.4)

Less: Non-cash pension settlement income

(0.1)

Plus: Depreciation and amortization expense

37.7

37.4

153.5

119.3

EBITDA

$

68.5

$

94.4

$

225.9

$

307.0

Plus: Restructuring charges

3.8

1.0

9.9

6.2

Plus: Acquisition-related costs

3.5

7.3

17.0

29.1

Plus: Non-cash asset impairment charges

0.1

5.1

12.5

5.1

Plus: Non-cash pension settlement income

(0.1)

Plus: Incremental COVID-19 costs, net

0.6

1.9

Less: (Gain) loss on disposal of properties, plants, equipment, and
businesses, net

0.9

0.9

39.3

0.9

Adjusted EBITDA

$

77.4

$

108.7

$

306.4

$

348.3


Flexible Products & Services

Operating profit

$

4.8

$

3.1

$

15.5

$

25.3

Less: Other income, net

(0.9)

(0.3)

(1.3)

(1.2)

Plus: Depreciation and amortization expense

1.2

1.5

5.6

6.2

EBITDA

$

6.9

$

4.9

$

22.4

$

32.7

Plus: Restructuring charges

1.5

1.0

2.8

1.0

Plus: Non-cash asset impairment charges

0.9

Plus: Incremental COVID-19 costs, net

0.3

0.6

Less: (Gain) loss on disposal of properties, plants, equipment, and
businesses, net

0.1

(0.1)

0.1

(5.1)

Adjusted EBITDA

$

8.8

$

5.8

$

26.8

$

28.6


Land Management

Operating profit

$

2.2

$

1.9

$

8.5

$

9.9

Plus: Depreciation, depletion and amortization expense

1.4

1.1

4.5

4.3

EBITDA

$

3.6

$

3.0

$

13.0

$

14.2

Less: Gain  on disposal of properties, plants, equipment, and
businesses, net

(0.6)

(0.2)

(1.1)

(2.2)

Adjusted EBITDA

$

3.0

$

2.8

$

11.9

$

12.1

Consolidated EBITDA

$

152.6

$

173.9

$

545.9

$

605.5

Consolidated Adjusted EBITDA

$

154.5

$

186.8

$

642.6

$

658.9


(13)Adjusted EBITDA is defined as net income, plus interest expense, net, plus income tax expense, plus depreciation, depletion and amortization expense, plus restructuring charges, plus acquisition-related costs, plus non-cash impairment charges, plus incremental COVID-19 costs, net, plus non-cash pension settlement (income) charges, less (gain) loss on disposal of properties, plants, equipment and businesses, net. However, because the Company does not calculate net income by segment, this table calculates adjusted EBITDA by segment with reference to operating profit by segment, which, as demonstrated in the table of consolidated adjusted EBITDA, is another method to achieve the same result.

 


GREIF, INC. AND SUBSIDIARY COMPANIES


GAAP TO NON-GAAP RECONCILIATION


ADJUSTED FREE CASH FLOW(14)

UNAUDITED


Three Months Ended
October 31,


Twelve Months Ended
October 31,


(in millions)


2020


2019


2020


2019


Net cash provided by operating activities

$

200.4

$

195.4

$

454.7

$

389.5

Cash paid for purchases of properties, plants and equipment

(32.6)

(53.0)

(131.4)

(156.8)


Free Cash Flow

$

167.8

$

142.4

$

323.3

$

232.7

Cash paid for acquisition-related costs

3.5

7.5

17.0

29.7

Cash paid for debt issuance costs

5.1

Cash paid for incremental COVID-19 costs, net

0.7

2.6

Cash paid for acquisition-related ERP systems

1.9

0.3

3.3

0.3


Adjusted Free Cash Flow

$

173.9

$

150.2

$

346.2

$

267.8


(14)Adjusted free cash flow is defined as net cash provided by (used in) operating activities, less cash paid for purchases of properties, plants and equipment, plus cash paid for acquisition-related costs, plus cash paid for debt issuance costs, plus cash paid for incremental COVID-19 costs, net, plus cash paid for acquisition-related ERP systems.

 


GREIF, INC. AND SUBSIDIARY COMPANIES


GAAP TO NON-GAAP RECONCILIATION


NET INCOME, CLASS A EARNINGS PER SHARE, AND TAX RATE BEFORE ADJUSTMENTS

UNAUDITED


(in millions, except for per share amounts)


Income before
Income Tax
Expense and
Equity
Earnings of
Unconsolidated
Affiliates, net


Income
Tax
(Benefit)
Expense


Equity
Earnings


Noncontrolling
Interest


Net Income
Attributable
to Greif, Inc.


Diluted
Class A
Earnings
Per
Share


Tax Rate


Three Months Ended October 31, 2020

$

66.2

$

18.5

$

(0.3)

$

3.6

$

44.4

$

0.74

27.9

%

(Gain) loss on disposal of properties, plants,
equipment and businesses, net

(16.2)

(5.2)

(11.0)

(0.19)

Restructuring charges

11.9

2.9

0.6

8.4

0.14

Non-cash asset impairment charges

1.6

0.4

1.2

0.02

Acquisition-related costs

3.5

0.9

2.6

0.05

Non-cash pension settlement charges

0.4

0.4

0.01

Incremental COVID-19 costs, net

0.7

0.3

0.4

0.01

Excluding Adjustments

$

68.1

$

17.8

$

(0.3)

$

4.2

$

46.4

$

0.78

26.1

%


Three Months Ended October 31, 2019

$

81.7

$

12.4

$

(0.5)

$

4.8

$

65.0

$

1.09

15.2

%

(Gain) loss on disposal of properties, plants,
equipment and businesses, net

(6.1)

(1.8)

(4.3)

(0.07)

Restructuring charges

5.8

(0.1)

0.7

5.2

0.09

Non-cash asset impairment charges

5.7

1.9

0.1

3.7

0.06

Acquisition-related costs

7.5

7.5

0.13

Tax net benefit resulting from the Tax Reform Act

3.7

(3.7)

(0.06)

Excluding Adjustments

$

94.6

$

16.1

$

(0.5)

$

5.6

$

73.4

$

1.24

17.0

%


Twelve Months Ended October 31, 2020

$

186.1

$

63.3

$

(1.5)

$

15.5

$

108.8

$

1.83

34.0

%

(Gain) loss on disposal of properties, plants,
equipment and businesses, net

19.6

(4.7)

0.6

23.7

0.40

Restructuring charges

38.7

9.0

1.0

28.7

0.48

Non-cash asset impairment charges

18.5

3.9

14.6

0.25

Acquisition-related costs

17.0

4.1

12.9

0.22

Non-cash pension settlement charges

0.3

0.3

0.01

Incremental COVID-19 costs, net

2.6

0.7

1.9

0.03

Excluding Adjustments

$

282.8

$

76.3

$

(1.5)

$

17.1

$

190.9

$

3.22

27.0

%


Twelve Months Ended October 31, 2019

$

262.0

$

70.7

$

(2.9)

$

23.2

$

171.0

$

2.89

27.0

%

(Gain) loss on disposal of properties, plants,
equipment and businesses, net

(10.2)

(2.4)

(2.5)

(5.3)

(0.09)

Restructuring charges

26.1

4.4

0.8

20.9

0.36

Non-cash asset impairment charges

7.8

1.9

0.1

5.8

0.10

Acquisition-related costs

29.7

4.3

25.4

0.43

Debt extinguishment charges

22.0

5.3

16.7

0.28

Tax net benefit resulting from the Tax Reform
Act

0.5

(0.5)

(0.01)

Excluding Adjustments

$

337.4

$

84.7

$

(2.9)

$

21.6

$

234.0

$

3.96

25.1

%

The impact of income tax expense and noncontrolling interest on each adjustment is calculated based on tax rates and ownership percentages specific to each applicable entity.

 


GREIF, INC. AND SUBSIDIARY COMPANIES


GAAP TO NON-GAAP RECONCILIATION


NET SALES TO NET SALES EXCLUDING THE IMPACT OF


CURRENCY TRANSLATION

UNAUDITED


Three Months Ended
October 31,


(in millions)


2020


2019


Increase
(Decrease) in
Net Sales ($)


Increase
(Decrease) in
Net Sales (%)


Consolidated

Net Sales

$

1,161.3

$

1,232.1

$

(70.8)

(5.7)

%

Currency Translation

0.9

N/A

Net Sales Excluding the Impact of Currency Translation

$

1,160.4

$

1,232.1

$

(71.7)

(5.8)

%


Rigid Industrial Packaging & Services

Net Sales

$

579.1

$

619.0

$

(39.9)

(6.4)

%

Currency Translation

(1.0)

N/A

Net Sales Excluding the Impact of Currency Translation

$

580.1

$

619.0

$

(38.9)

(6.3)

%


Paper Packaging & Services

Net Sales

502.3

535.1

$

(32.8)

(6.1)

%

Currency Translation

N/A

Net Sales Excluding the Impact of Currency Translation

$

502.3

$

535.1

$

(32.8)

(6.1)

%


Flexible Products & Services

Net Sales

73.2

70.9

$

2.3

3.2

%

Currency Translation

1.9

N/A

Net Sales Excluding the Impact of Currency Translation

$

71.3

$

70.9

$

0.4

0.6

%


Twelve Months Ended
October 31,


(in millions)


2020


2019


Increase in
Net Sales ($)


Increase in
Net Sales (%)


Consolidated

Net Sales

$

4,515.0

$

4,595.0

$

(80.0)

(1.7)

%

Currency Translation

(43.0)

N/A

Net Sales Excluding the Impact of Currency Translation

$

4,558.0

$

4,595.0

$

(37.0)

(0.8)

%


Rigid Industrial Packaging & Services

Net Sales

$

2,298.9

$

2,490.6

$

(191.7)

(7.7)

%

Currency Translation

(39.6)

N/A

Net Sales Excluding the Impact of Currency Translation

$

2,338.5

$

2,490.6

$

(152.1)

(6.1)

%


Paper Packaging & Services

Net Sales

1,916.9

1,780.0

$

136.9

7.7

%

Currency Translation

(0.4)

N/A

Net Sales Excluding the Impact of Currency Translation

$

1,917.3

$

1,780.0

$

137.3

7.7

%


Flexible Products & Services

Net Sales

272.9

297.5

$

(24.6)

(8.3)

%

Currency Translation

(3.0)

N/A

Net Sales Excluding the Impact of Currency Translation

$

275.9

$

297.5

$

(21.6)

(7.3)

%

 


GREIF, INC. AND SUBSIDIARY COMPANIES


 GAAP TO NON-GAAP RECONCILIATION


 NET DEBT

UNAUDITED


(in millions)


October 31, 2020


October 31, 2019

Total Debt

$

2,487.0

$

2,751.9

Cash and cash equivalents

(105.9)

(77.3)


Net Debt

$

2,381.1

$

2,674.6

 

Contact:   
Matt Eichmann
740-549-6067
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/greif-reports-fourth-quarter-and-fiscal-2020-results-301189892.html

SOURCE Greif, Inc.